HOME
>
臨床医学：外科
>
麻酔科学/ペイン
> 麻酔科医のための周術期の薬物使用法

麻酔科医のための周術期の薬物使用法

出版社：	中山書店
著者：	川真田樹人(専門編集)
発行日：	2015-05-15
分野：	臨床医学：外科 > 麻酔科学/ペイン
ISBN：	9784521737126
シリーズ：	新戦略に基づく麻酔・周術期医学
電子書籍版：	2015-05-15 （初版第1刷）

書籍・雑誌

≪全国送料無料でお届け≫

取寄せ目安：8～14営業日

16,500 円(税込)

購入する

電子書籍

章別単位での購入はできません

ブラウザ、アプリ閲覧

16,500 円(税込)

購入する

商品紹介

麻酔科医は、安全かつ有効な全身管理を行うために、周術期に使用する多くの薬物の詳細な知識を必要とする。本書では、まず麻酔薬，全身管理薬などの各薬物を概説し、次いで個々の薬物の使い分け、作用機序や具体的な使用方法について、豊富な図表を用いて分かりやすく簡潔に解説した。周術期に使用する薬物の基礎的な事項から実践的な使用法まで、知識を整理して一歩進んだ薬物使用法を学べる１冊。

目次

麻酔科医のための周術期の薬物使用法

―目次―

1章　術前使用薬物
2章　麻酔薬、麻酔関連薬
3章　全身管理薬
4章　輸液、輸血
5章　抗菌薬
6章　抗ウイルス薬、抗真菌薬
7章　周術期、ICUにおける栄養

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

1章術前使用薬物

P.8 掲載の参考文献

1) Devereaux PJ, et al. Clonidine in patients undergoing noncardiac surgery. N Engl J Med 2014 ; 370 : 1504-13.

2) Sanders RD, et al : Perioperative statin therapy for improving outcomes during and after noncardiac vascular surgery. Cochrane Database Syst Rev 2013 Jul 3 ; 7 : CD009971.

3) Colson P, et al. Renin angiotensin system antagonists and anesthesia. Anesth Analg 1999 ; 89 : 1143-55.

4) Burger W, et al. Low-dose aspirin for secondary cardiovascular prevention-cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation-review and meta-analysis. J Intern Med 2005 ; 257 : 399-414.

5) Horlocker TT, et al : Regional anesthesia in the anticoagulated patient : Defining the risks (the second ASRA Consensus Conference on Neuraxial Anesthesia and Anticoagulation). Reg Anesth Pain Med 2003 ; 28 : 172-97.

6) Wu CL. Managing postoperative pain in the opioid-tolerant patient : careful planning provides optimal pain control, minimizes problems. J Crit Illness 2002 ; 17 : 426-32.

P.12 掲載の参考文献

1) 日本高血圧学会高血圧治療ガイドライン作成委員会, 編. 高血圧治療ガイドライン 2014. ライフサイエンス出版 ; 2014. p. 46.

2) Tuman KJ, et al. Angiotensin-converting enzyme inhibitors increase vasoconstrictor requirements after cardiopulmonary bypass. Anesth Analg 1995 ; 80 : 473-9.

3) Brabant SM, et al. Refractory hypotension after induction of anesthesia in a patient chronically treated with angiotensin receptor antagonists. Anesth Analg 1999 ; 89 : 887-8.

4) Coriat P, et al. Influence of chronic angiotensin-converting enzyme inhibition on anesthetic induction. Anesthesiology 1994 ; 81 : 299-307.

5) Hasija S, et al. Prophylactic vasopressin in patients receiving the angiotensinconverting enzyme inhibitor ramipril undergoing coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth 2010 ; 24 : 230-8.

6) London, MJ, et al. Association of perioperative β-blockade with mortality and cardiovascular morbidity following major noncardiac surgery. JAMA 2013 ; 309 : 1704-13.

7) Fleisher LA, et al. 2009 ACCF/AHA focused update on perioperative beta blockade incorporated into the ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery : A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2009 ; 120 : e169-276.

8) Ashes C, et al. Selective β1-antagonism with bisoprolol is associated with fewer postoperative strokes than atenolol or metoprolol. Anesthesiology 2013 ; 119 : 777-87.

9) Tauzin-Fin P, et al. Effects of perioperative α1 block on haemodynamic control during laparoscopic surgery for phaeochromocytoma. Br J Anaesth 2004 ; 92 : 512-7.

P.16 掲載の参考文献

1) Clement S, et al. Management of diabetes and hyperglycemia in hospitals. Diabetes Care 2004 ; 27 : 553-91.

2) Marks JB. Perioperative management of diabetes. Am Fam Physician 2003 ; 67 : 93-100.

P.20 掲載の参考文献

1) 日本呼吸器学会COPDガイドライン第２版作成委員会, 編. COPD (慢性閉塞性肺疾患) 診断と治療のためのガイドライン第2版. 東京 : メディカルレビュー社 ; 2004.

2) 社団法人日本アレルギー学会喘息ガイドライン専門部会, 監修. 喘息予防・管理ガイドライン 2009. 東京 : 協和企画 ; 2009.

3) Spruit MA, et al ; ATS/ERS Task Force on Pulmonary Rehabilitation. An official American Thoracic Society/European Respiratory Society statement : Key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med 2013 ; 188 : e13-64.

4) Russi EW, et al ; Swiss Respiratory Society. Diagnosis and management of chronic obstructive pulmonary disease : The Swiss guidelines. Official guidelines of the Swiss Respiratory Society. Respiration 2013 ; 85 : 160-74.

5) Miravitlles M, et al ; Spanish Society of Pulmonology and Thoracic Surgery. Spanish COPD Guidelines (GesEPOC) : Pharmacological treatment of stable COPD. Spanish Society of Pulmonology and Thoracic Surgery. Arch Bronconeumol 2012 ; 48 : 247-57.

6) Hanania NA, Marciniuk DD. A unified front against COPD : Clinical practice guidelines from the American College of Physicians, the American College of Chest Physicians, the American Thoracic Society, and the European Respiratory Society. Chest 2011 ; 140 : 565-6.

7) Qaseem A, et al ; American College of Physicians ; American College of Chest Physicians ; American Thoracic Society ; European Respiratory Society. Diagnosis and management of stable chronic obstructive pulmonary disease : A clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med 2011 ; 155 : 179-91.

8) Abdool-Gaffar MS, et al ; COPD Working Group. Guideline for the management of chronic obstructive pulmonary disease--2011 update. S Afr Med J 2011 ; 101 (1 Pt 2) : 63-73. Erratum in : S Afr Med J 2011 ; 101 : 288.

9) Marciniuk DD, et al ; Canadian Thoracic Society COPD Committee Expert Working Group. Optimizing pulmonary rehabilitation in chronic obstructive pulmonary disease--practical issues : A Canadian Thoracic Society Clinical Practice Guideline. Can Respir J 2010 ; 17 : 159-68.

10) Kling S, et al ; South African Childhood Asthma Working Group (SACAWG). Guideline for the management of acute asthma in children : 2013 update. S Afr Med J 2013 ; 103 (3 Pt 3) : 199-207.

11) Dweik RA, et al ; American Thoracic Society Committee on Interpretation of Exhaled Nitric Oxide Levels (FENO) for Clinical Applications. An official ATS clinical practice guideline : Interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med 2011 ; 184 : 602-15.

12) Joint Task Force on Practice Parameters. Attaining optimal asthma control : a practice parameter. J Allergy Clin Immunol 2005 ; 116 : S3-11.

13) Becker A, et al ; Asthma Guidelines Working Group of the Canadian Network For Asthma Care. Summary of recommendations from the Canadian Asthma Consensus guidelines, 2003. CMAJ 2005 ; 173 (6 Suppl) : S3-11.

P.23 掲載の参考文献

1) Hench PS, et al. The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone ; compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. Proc Staff Meet Mayo Clin 1949 ; 24 : 181-97.

2) Jabbour SA. Steroids and the surgical patient. Med Clin North Am 2001 ; 85 : 1311-7.

3) Coursin DB, Wood KE. Corticosteroid supplementation for adrenal insufficiency. JAMA 2002 ; 287 : 236-40.

4) Jung C, Inder WJ. Management of adrenal insufficiency during the stress of medical illness and surgery. Med J Aust 2008 ; 188 : 409-13.

5) Esteban NV, et al. Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry. J Clin Endocrinol Metab 1991 ; 72 : 39-45.

6) Kerrigan JR, et al. Estimation of daily cortisol production and clearance rates in normal pubertal males by deconvolution analysis. J Clin Endocrinol Metab 1993 ; 76 : 1505-10.

7) Weitzman ED, et al. Twenty-four hour pattern of the episodic secretion of cortisol in normal subjects. J Clin Endocrinol Metab 1971 ; 33 : 14-22.

8) Kehlet H. A rational approach to dosage and preparation of parenteral glucocorticoid substitution therapy during surgical procedures. A short review. Acta Anaesthesiol Scand 1975 ; 19 : 260-4.

9) Kehlet H, Binder C. Adrenocortical function and clinical course during and after surgery in unsupplemented glucocorticoid-treated patients. Br J Anaesth 1973 ; 45 : 1043-8.

10) LaRochelle GE Jr, et al. Recovery of the hypothalamic-pituitary-adrenal (HPA) axis in patients with rheumatic diseases receiving low-dose prednisone. Am J Med 1993 ; 95 : 258-64.

11) Mohler JL, et al. Adrenal insufficiency following unilateral adrenalectomy : A case report. J Urol 1986 ; 135 : 554-6.

12) Alford WC Jr, et al. Acute adrenal insufficiency following cardiac surgical procedures. J Thorac Cardiovasc Surg 1979 ; 78 : 489-93.

13) Rivers EP, et al. Adrenal insufficiency in high-risk surgical ICU patients. Chest 2001 ; 119 : 889-96.

14) de Lange DW, Kars M. Perioperative glucocorticosteroid supplementation is not supported by evidence. Eur J Intern Med 2008 ; 19 : 461-7.

15) Yong SL, et al. Supplemental perioperative steroids for surgical patients with adrenal insufficiency. Cochrane Database Syst Rev 2012 ; 12 : CD00536.

P.26 掲載の参考文献

1) Perks A, et al. Anesthesia and epilepsy. Br J Anaesth 2012 ; 108 : 562-71.

2) Voss LJ, et al. The howling cortex : Seizures and general anesthetic drugs. Anesth Analg 2008 ; 107 : 1689-703.

3) Kim MH, et al. Effects of valproic acid and magnesium sulphate on rocuronium requirement in patients undergoing craniotomy for cerebrovascular surgery. Br J Anaesth 2012 ; 109 : 407-12.

P.30 掲載の参考文献

1) 長田大雅, 高野学美. 26 向精神薬長期大量服薬, 無痙攣性電気ショック療法. 武田純三, 監修, 高野学美, 忍田純哉, 編. 合併症患者の麻酔スタンダード. 東京 : 克誠堂出版 ; 2008. p. 191-7.

2) 中井哲慈. 精神疾患を持つ患者の麻酔概論. 臨床麻酔 2013 ; 37 : 1298-304.

3) 柏木政憲. 36 認知症, パーキンソン病. 武田純三, 監修, 高野学美, 忍田純哉, 編. 合併症患者の麻酔スタンダード. 東京 : 克誠堂出版 ; 2008. p. 271-3.

4) 森本裕二, ほか. 精神・神経疾患患者の麻酔. 劔物修, ほか編. NEW麻酔科学. 改訂第３版. 東京 : 南江堂 ; 2001. p. 33-4

P.36 掲載の参考文献

1) 肺血栓塞栓症/深部静脈血栓症 (静脈血栓塞栓症) 予防ガイドライン作成委員会. 肺血栓塞栓症/深部静脈血栓症 (静脈血栓塞栓症) 予防ガイドライン・ダイジェスト版第2版. 東京 : メディカルフロントインターナショナル ; 2004.

2) 黒岩政之. 周術期静脈血栓塞栓症における薬物予防-麻酔科医の立場から <日本麻酔科学会周術期肺塞栓症調査結果より>. 日臨麻会誌 2010 ; 30 : 996-1001.

3) 日本有病者歯科医療学会, ほか編. 抗血栓療法ガイドライン推進選定部会委員会. 科学的根拠に基づく抗血栓療法患者の抜歯に関するガイドライン2010年版. 東京 : 学術社 ; 2010.

4) 日本循環器学会, ほか. 循環器疾患における抗凝固・抗血小板療法に関するガイドライン (2009年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2009_hori_h.pdf

5) 日本循環器学会, ほか. 肺血栓塞栓症および深部静脈血栓症の診断, 治療, 予防に関するガイドライン (2009年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2009_andoh_h.pdf

6) Hirsh J, et al. The sixth (2000) ACCP guidelines for antithrombotic therapy for prevention and treatment of thrombosis. American College of Chest Physicians. Chest 2001 ; 119 (1 suppl) : 1S-2S.

7) 日本消化器内視鏡学会, ほか編. 抗血栓薬服用者に対する消化器内視鏡診療ガイドライン. 日本消化器内視鏡学会雑誌 2012 ; 54 : 2073-102.

8) Heidbuchel H, et.al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013 ; 15 : 625-51.

9) Horlocker, TT, et al. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy : American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Third Edition). Reg Anesth Pain Med 2010 ; 35 : 64-101.

2章麻酔薬, 麻酔関連薬

P.42 掲載の参考文献

1) Bailey PL, et al. Intravenous opioid anesthetics. In : Miller RD, ed. Anesthesia. 5th ed. New York : Elsevier, Churchill Livingstone ; 2000. p. 273-376.

2) Fields HL, et al. Neurotransmitters in nociceptive modulatory circuits. Annu Rev Neurosci 1991 ; 14 : 219-45.

3) Fukuda K. Opioids. In : Miller RD, ed. Miller's Anesthesia. 7th ed. New York : Elsevier, Churchill Livingstone, 2009. p. 769-824.

4) Weissman C. The metabolic response to stress : An overview and update. Anesthesiology 1990 ; 73 : 308-27.

5) Shafer SL, Schwinn AA. Basic principles of pharmacology related to anesthesia. In : Miller RD, ed. Miller's Anesthesia. 6th ed. New York : Elsevier, Churchill Livingstone ; 2005. p. 67-104.

P.45 掲載の参考文献

1) Albertin A, et al. The effect-site concentration of remifentanil blunting cardiovascular responses to tracheal intubation and skin incision during bispectral index-guided propofol anesthesia. Anesth Analg 2005 ; 101 : 125-30.

2) Minto CF, et al. Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. Anesthesiology 1997 ; 86 : 10-23.

3) Niesters M, et al. High-inspired oxygen concentration further impairs opioid-induced respiratory depression. Br J Anaesth 2013 ; 110 : 837-41.

4) van Gulik L, et al. Remifentanil during cardiac surgery is associated with chronic thoracic pain 1 yr after sternotomy. Br J Anaesth 2012 ; 109 : 616-22.

P.48 掲載の参考文献

1) Peng PW, Sandler AN. A review of the use of fentanyl analgesia in the management of acute pain in adults. Anesthesiology 1999 ; 90 : 576-99.

2) Ginosar Y, et al. The site of action of epidural fentanyl in humans : The difference between infusion and bolus administration. Anesth Analg 2003 ; 97 : 1428-38.

3) Schnider TW, Minto CF. Predictors of onset and offset of drug effect. Eur J Anaesthesiol Suppl 2001 ; 23 : 26-31.

4) Scott JC, Stanski DR. Decreased fentanyl and alfentanil dose requirements with age. A simultaneous pharmacokinetic and pharmacodynamic evaluation. J Pharmacol Exp Ther 1987 ; 240 : 159-66.

5) 林和子, ほか. シミュレーションに基づいたIV-PCAメニューの設定と応用. 日本臨床麻酔学会誌 2012 ; 32 : 814-20.

6) Tsen LC. Anesthesia for cesarean delivery. In : Chestnut DH, et al, eds. Chestnut's Obstetric Anesthesia : Principles and Practice. 5th ed. Philadelphia : Elsevier, Saunders ; 2014. p. 545-603.

7) Apfel CC, et al. Evidence-based analysis of risk factors for postoperative nausea and vomiting. Br J Anaesth 2012 ; 109 : 742-53.

P.51 掲載の参考文献

1) Mignat C, et al. Affinity profiles of morphine, codeine, dihydrocodeine and their glucuronides at opioid receptor subtypes. Life Sci 1995 ; 56 : 793-9.

2) Stuart-Harris R, et al. The pharmacokinetics of morphine and morphine glucuronide metabolites after subcutaneous bolus injection and subcutaneous infusion of morphine. Br J Clin Pharmacol 2000 ; 49 : 207-14.

3) Kawano T, Yokoyama M. Relationship between analgesic dose of morphine and vomiting in rat model of postoperative acute pain. PAIN RESEARCH 2012 ; 27 : 227-31.

P.54 掲載の参考文献

1) Bentley KW, et al. Novel analgesics and molecular rearrangements in the morphinethebaine group. II. Alcohols derived from 6,14-endo-etheno-and 6,14-endo-ethanotetrahydrothebaine. J Am Chem Soc 1967 ; 89 : 3273-80.

2) Pick CG, et al. Pharmacological characterization of buprenorphine : A mixed agonistantagonist with κ3 analgesia. Brain Res 1997 ; 744 : 41-6.

3) Heel RC, et al. Buprenorphine : A review of its pharmacological properties and therapeutic efficacy. Drugs 1979 ; 17 : 81-110.

4) 平田純生, ほか. 付表 : 腎機能低下時の薬剤投与量. 日本腎臓学会, 編. CKD診療ガイド 2012. 東京 : 東京医学社 ; 2012. p. 106-7.

5) Bullingham RES, et al. Buprenorphine kinetics. Clin Pharmacol Ther 1980 ; 28 : 667-72.

6) Huang P, et al. Comparison of pharmacological activities of buprenorphine and norbuprenorphine : Norbuprenorphine is a potent opioid agonist. J Pharmacol Exp Ther 2001 ; 297 : 688-95.

7) Brown SM, et al. P-Glycoprotein is a major determinant of norbuprenorphine brain exposure and antinociception. J Pharmacol Exp Ther 2012 ; 343 : 53-61.

8) Yassen A, et al. Pharmacokinetic?pharmacodynamic modeling of the effectiveness and safety of buprenorphine and fentanyl in rats. Pharm Res 2008 ; 25 : 183-93.

P.57 掲載の参考文献

1) Fukuda K. Opioids. In : Miller RD, ed. Miller's Anesthesia. 7th ed. Philadelphia : Elsevier, Churchill Livingstone ; 2009. p. 769-824.

2) Stoelting RK. Opioid agonists and antagonists. Stoelting RK, Hiller SC, eds. Pharmacology and Physiology in Anesthetic Practice. 4th ed. Philadelphia : Lippincott Williams & Wilkins ; 2005. p. 87-126.

3) Yaksh TL, Wallace MS. Opioids, analgesia, and pain management. Brunton L, et al, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 12th ed. New York : McGraw-Hill Professional ; 2010. p. 481-525.

4) Kurz A, et al. Meperidine decreases the shivering threshold twice as much as the vasoconstriction threshold. Anesthesiology 1997 ; 86 : 1046-54.

5) Park SM, et al. Efficacy spectrum of antishivering medications : Meta-analysis of randomized controlled trials. Crit Care Med 2012 ; 40 : 3070-82.

P.59 掲載の参考文献

1) 佐伯茂. ペンタゾシン. ペインクリニック 2005 ; 26 : S179-86.

2) Gutstein HB, Akil H. Opioid analgesics. In : Hardman JG, Limbird LE, eds. Goodman & Gillman's The Pharmacological Basis of Therapeutics. 10th ed. New York : MacGraw-Hill Professional ; 2001. p. 569-619.

3) 井出康雄. ペンタゾシン. ペインクリニック 2012 ; 33 : S459-64.

4) Levine JD, Gordon NC. Synergism between the analgesic actions of morphine and pentazocine. Pain 1988 ; 33 : 369-72.

5) Shu H, et al. Pentazocine-induced antinociception is mediated mainly by μ-opioid receptors and compromised by κ-opioid receptors in mice. J Pharmacol Exp Ther 2011 ; 338 : 579-87.

6) Preston KL, Bigelow GE. Differential naltrexone antagonism of hydromorphone and pentazocine effects in human volunteers. J Pharmacol Exp Ther 1993 ; 264 : 813-23.

7) Pan ZZ. μ-Opposing actions of theκ-opioid receptor. Trends Pharmacol Sci 1998 ; 19 : 95-8.

8) 木村信康, ほか. ペンタゾシン錠 (ソセゴン, ペンタジン, ペルタゾン). ペインクリニック 2008 ; 29 : S603-7.

9) 大塚みき子. ペンタゾシンを用いたIV PCA. 日本臨床麻酔学会誌 2010 ; 30 : 29-35.

10) Fukuda K. Opioid. In : Miller RD, ed. Miller's Anesthesia. 7th ed. Philadelphia : Elsevier, Churchill Livingstone ; 2010. p. 769-824.

P.61 掲載の参考文献

1) Miller RD, ed. Anesthesia. 6th ed. Philadeiphia : Elsevier, Churchill Livingstone ; 2005. p. 420-1.

2) 瀬戸口大典, ほか. ナロキソン. 麻酔 2013 ; 62 : 5-9.

3) McGilliard KL, Takemori AE. Antagonism by naloxone of narcotic-induced respiratory depression and analgesia. J Pharmacol Exp Ther 1978 ; 207 : 494-503.

4) Wermeling DP. A Response to the Opioid Overdose Epidemic : Naloxone Nasal Spray. Drug Deliv Transl Res 2013 ; 3 : 63-74.

5) 日本麻酔科学会. II 鎮痛薬・拮抗薬. 麻酔薬および麻酔関連薬使用ガイドライン第3版. 2009. p. 56-8. http://www.anesth.or.jp/guide/pdf/publication4-2_20121106.pdf

6) Just B et al. Oxygen uptake during recovery following naloxone. Relationship with intraoperative heat loss. Anesthesiology 1992 ; 76 : 60-4.

P.63 掲載の参考文献

1) Mitchell RA, Herbert DA. Potencies of doxapram and hypoxia in stimulating carotidbody chemoreceptors and ventilation in anesthetized cats. Anesthesiology 1975 ; 42 : 559-66.

2) Yost CS. A new look at the respiratory stimulant doxapram. CNS Drug Rev 2006 ; 12 : 236-49.

3) 日本麻酔科学会. XII その他. 8. 呼吸中枢刺激薬. 麻酔薬および麻酔関連薬使用ガイドライン第3版. 2012. p. 711-2. http://www.anesth.or.jp/guide/pdf/publication4-12_20121106.pdf

4) Gupta PK, et al. Hastening of arousal after general anaesthesia with doxapram hydrochloride. Br J Anaesth 1973 ; 45 : 493-6.

5) Robertson GS, et al. Evaluation of doxapram for arousal from general anaesthesia in outpatients. Br J Anaesth 1977 ; 49 : 133-40.

6) Komatsu R, et al. Doxapram only slightly reduces the shivering threshold in healthy volunteers. Anesth Analg 2005 ; 101 : 1368-73.

7) Prins SA, et al. Doxapram use for apnoea of prematurity in neonatal intensive care. Int J Pediatr 2013 ; 2013 : 251047. Epub 2013 Nov 26.

P.69 掲載の参考文献

1) Jensen LS, et al. Evidence-based strategies for preventing drug administration errors during anaesthesia. Anaesthesia 2004 ; 59 : 493-504.

2) 川口陽子, ほか. プロポフォール投与中止4.5時間後血漿濃度が 4.4 μg・ml (-1) と高濃度であった覚醒遅延の1症例. 麻酔 2010 ; 59 : 1510-13.

3) Winstock AR, et al. The prevalence and natural history of urinary symptoms among recreational ketamine users. BJU Int 2012 ; 110 : 1762-66.

4) Pizov R, et al. Wheezing during induction of general anesthesia in patients with and without asthma. A randomized, blinded trial. Anesthesiology 1995 ; 82 : 1111-16.

5) Nuttall GA, et al. Does low-dose droperidol increase the risk of polymorphic ventricular tachycardia or death in the surgical patient? Anesthesiology 2013 ; 118 : 382-86.

6) Vasile B, et al. The pathophysiology of propofol infusion syndrome : A simple name for a complex syndrome. Intensive Care Med 2003 ; 29 : 1417-25.

7) Footitt EJ, et al. Mitochondrial disorders and general anaesthesia : A case series and review. Br J Anaesth 2008 ; 100 : 436-41.

P.71 掲載の参考文献

1) Hughes MA, et al. Context-sensitive half-time in multicompartment pharmacokinetic models for intravenous anesthetic drugs. Anesthesiology 1992 ; 76 : 334-41.

2) Schnider TW, et al. The influence of age on propofol pharmacodynamics. Anesthesiology 1999 ; 90 : 1502-16.

3) 小板橋俊哉, ほか. プロポフォールによる注入時血管痛の発現頻度および強度に与える年齢の影響. 臨床麻酔 2004 ; 28 : 1657-61.

P.74 掲載の参考文献

1) Liu H, et al. Effect of thiopental sodium on N-methyl-d-aspartate-gated currents. Can J Anaesth 2006 ; 53 : 442-8.

2) Celleno D, et al. Neurobehavioural effects of propofol on the neonate following elective caesarean section. Br J Anaesth 1989 ; 62 : 649-54.

3) Nussmeier NA, et al. Neuropsychiatric complications after cardiopulmonary bypass : Cerebral protection by a barbiturate. Anesthesiology 1986 ; 64 : 165-70.

4) Mseddi MA, et al. Fatal postoperative crisis in acute hereditary porphyria. Tunis Med 2002 ; 80 : 288-91.

P.77 掲載の参考文献

1) Richter L, et al. Diazepam-bound GABAA receptor models identify new benzodiazepine binding-site ligands. Nat Chem Biol 2012 ; 8 : 455-64.

2) Riker RR, et al. Dexmedetomidine vs midazolam for sedation of critically ill patients : A randomized trial. JAMA 2009 ; 301 : 489-99.

3) Fraser GL, et al. Benzodiazepine versus nonbenzodiazepine-based sedation for mechanically ventilated, critically ill adults : A systematic review and meta-analysis of randomized trials. Crit Care Med 2013 ; 41 : S30-8.

4) Barr J, et al. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Crit Care Med 2013 ; 41 : 263-306.

5) Morita T, et al. Correlation of the dose of midazolam for symptom control with administration periods : The possibility of tolerance. J Pain Symptom Manage 2003 ; 25 : 369-75.

6) Kilpatrick GJ, et al. CNS 7056 : A novel ultra-short-acting Benzodiazepine. Anesthesiology 2007 ; 107 : 60-6.

P.80 掲載の参考文献

1) 水野樹. フルマゼニル. 麻酔 2013 ; 62 : 10-8.

2) Hoffman EJ, Warren EW. Flumazenil : A benzodiazepine antagonist. Clin Pharm 1993 ; 12 : 641-56.

3) 関野久之, ほか. YM684 (Flumazenil) の臨床第I相試験. 医学と薬学 1990 ; 23 : 777-96.

4) 今崎一, ほか. 14C-YM684をラットに静脈内投与した時の体内動態. 基礎と臨床 1990 ; 24 : 4425-35.

5) Bodenham A, Park GR. Reversal of prolonged sedation using flumazenil in critically ill patients. Anaesthesia 1989 ; 44 : 603-5.

6) 水野樹, ほか. 上部消化管内視鏡検査におけるミダゾラム静注鎮静後フルマゼニル拮抗法. 日本農村医学会雑誌 2004 ; 52 : 823-30.

7) Hojer J, et al. Diagnostic utility of flumazenil in coma with suspected poisoning : A double blind, randomised controlled study. BMJ 1990 ; 301 : 1308-11.

8) Weinbroum A, et al. Use of flumazenil in the treatment of drug overdose : A doubleblind and open clinical study in 110 patients. Crit Care Med 1996 ; 24 : 199-206.

9) Spivey WH. Flumazenil and seizures : Analysis of 43 cases. Clin Ther 1992 ; 14 : 292-305.

10) Burr W, et al. Death after flumazenil. BMJ 1989 ; 298 : 1713.

11) Chiolero RL, et al. The effects of midazolam reversal by RO 15-1788 on cerebral perfusion pressure in patients with severe head injury. Intensive Care Med 1988 ; 14 : 196-200.

12) Nishiyama T, et al. Continuous sedation with midazolam and reversal by flumazenil in patients with cirrhotic or non-cirrhotic liver damage. Anesth Resus 2002 ; 38 : 237-42.

13) Park GR, Podkowik BI. Plasma concentrations of flumazenil during liver transplantation. Anaesthesia 1992 ; 47 : 887-9.

P.84 掲載の参考文献

1) Reves JG, et al. Intravenous nonopioid anesthetics. In : Miller RD, ed. Miller's Anesthesia. 6th ed. philadelphia : Elsevier, Churchill Livingstone ; 2005. 武田純三, 監修. 稲田英一, ほか監訳. 非オピオイド静脈麻酔薬. ミラー麻酔科学. 原著第6版. 東京 : メディカル・サイエンス・インターナショナル ; 2007. p. 251-300.

2) Corssen G. Historical aspect of ketamine : First clinical experiences. In : Domino EF, ed. Status of Ketamine in Anesthesiology. NPP Books ; 1990. p. 1-6.

3) 日本麻酔科学会麻酔薬および麻酔関連薬使用ガイドライン第3版責任者小委員会. III 静脈麻酔薬. 麻酔薬および麻酔関連薬使用ガイドライン第3版. 2009. p. 83-96. http://www.anesth.or.jp/guide/pdf/publication4-3_20121106.pdf.

4) Petrenko AB, et al. Defining the role of NMDA receptors in anesthesia : Are we there yet? Eur J Pharmacol 2014 ; 723 : 29-37.

5) Haas DA, Harper DG. Ketamine : A review of its pharmacologic properties and use in ambulatory anesthesia. Anesth Prog 1992 ; 39 : 61-8.

6) Hirota K, et al. Stereoselective interaction of ketamine with recombinant mu, kappa, and delta opioid receptors expressed in Chinese hamster ovary cells. Anesthesiology 1999 ; 90 : 174-82.

7) Ostermann ME, et al. Sedation in the intensive care unit : A systematic review. JAMA 2000 ; 283 : 451-9.

P.87 掲載の参考文献

1) Lakhlani PP, et al. Substitution of a mutant α2a-adrenergic receptor via "hit and run" gene targeting reveals the role of this subtype in sedative, analgesic, and anestheticsparing responses in vivo. Proc Natl Acad Sci USA 1997 ; 94 : 9950-5.

2) Klimscha W, et al. Intrathecal α2-adrenergic agonists stimulate acetylcholine and norepinephrine release from the spinal cord dorsal horn in sleep. An in vivo microdialysis study. Anesthesiology 1997 ; 87 : 110-6.

3) Guo TZ, et al. Dexmedetomidine injection into the locus ceruleus produces antinociception. Anesthesiology 1996 ; 84 : 873-81.

4) 国沢卓之. デクスメデトミジンの薬物動態と薬力学. 日本臨床麻酔学会誌 2010 ; 30 : 181-9.

5) Nelson LE, et al. The α2-adrenoceptor agonist dexmedetomidine converges on an endogenous sleep-promoting pathway to exert its sedative effects. Anethesiology 2003 ; 98 : 428-36.

6) Pandhayipande PP, et al. Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients : the MENDS randomized controlled trial. JAMA 2007 ; 298 : 2644-53.

7) Arain SR, et al. The efficacy of dexmedetomidine versus morphine for postoperative analgesia after major inpatient surgery. Anesth Analg 2004 ; 98 : 153-8.

8) 原直樹. デクスメデトミジンの急性期・周術期使用. 日本臨床麻酔学会誌 2010 ; 30 : 216-23.

9) Bradley C. Dexmedetomidine-a novel sedative for postoperative sedation. Intensive Crit Care Nurs 2000 ; 16 : 328-9.

10) Bekker AY, et al. The use of dexmedetomidine infusion for awake craniotomy. Anesth Analg 2001 ; 92 : 1251-3.

P.90 掲載の参考文献

1) 槇田浩史, 山下哲秀. 悪心・嘔吐. 岩崎寛, 編. 麻酔科診療プラクティス 14. 麻酔偶発症・合併症. 文光堂 ; 2004. p. 125.

2) Miller, RD ed. Miller's Anesthesia, 6th ed. Philadelphia : Elsevier, Churchill Livingstone ; 2005. 武田純三, 監修. 稲田英一, ほか監訳. ミラー麻酔科学. 原著第6版. 東京 : メディカル・サイエンス・インターナショナル ; 2007. p. 285.

3) 小山伸一, ほか. ドロペリドール1.25 mg 術前静脈内投与はくも膜下モルヒネによる術後悪心・嘔吐を減少させる. 麻酔 2011 ; 60 : 173-9.

4) Fischler M, et al. The pharmacokinetics of droperidol in anesthetized patients. Anesthesiology 1986 ; 64 : 486-9.

5) 日本麻酔科学会 : 麻酔薬および麻酔関連薬使用ガイドライン第3版. III 静脈麻酔薬. 2009. p. 82-96. http://www.anesth.or.jp/guide/pdf/publication4-3_20121106.pdf

6) 小川彩絵, ほか. ドロペリドールの静脈内持続投与中に急性ジストニアをきたした1症例. 臨床麻酔 2012 ; 36 : 1797-8.

P.93 掲載の参考文献

1) Reves JG, et al. Intravenous nonopioid anesthetics. In : Miller RD, ed. Miller's Anesthesia. 6th ed. Philadelphia : Elsevier, Churchill Livingstone ; 2005. 武田純三, 監修. 稲田英一, ほか監訳. 非オピオイド静脈麻酔薬. ミラー麻酔科学. 原著第6版. 東京 : メディカル・サイエンス・インターナショナル ; 2007. p. 251-300.

2) Bergen JM, Smith DC. A review of etomidate for rapid sequence intubation in the emergency department. J Emerg Med 1997 ; 15 : 221-30.

3) Forman SA. Clinical and molecular pharmacology of etomidate. Anesthesiology 2011 ; 114 : 695-707.

4) Chan CM, et al. Etomidate is associated with mortality and adrenal insufficiency in sepsis : A meta-analysis. Crit Care Med 2012 ; 40 : 2945-53.

5) Jabre P, et al. Etomidate versus ketamine for rapid sequence intubation in acutely ill patients : A multicentre randomised controlled trial. Lancet 2009 ; 374 : 293-300.

P.99 掲載の参考文献

1) Foldes FF, et al. The neuromuscular effects of ORG9426 in patients receiving balanced anesthesia. Anesthesiology 1991 ; 75 : 191-6.

2) Cantineau JP, et al. Neuromuscular effects of rocuronium on the diaphragm and adductor pollicis muscles in anesthetized patients. Anesthesiology 1994 ; 81 : 585-90.

3) Suzuki T, et al. Effectiveness of the timing principle with high-dose rocuronium during rapid sequence induction with lidocaine, remifentanil and propofol. J Anesth 2010 ; 24 : 177-81.

4) 北島治, ほか. 高齢者におけるロクロニウムを用いたプライミングプリンシプルは有効か? 麻酔 2013 ; 62 : 148.

5) Fukano N, et al. A randomized trial to identify optimal precurarizing dose of rocuronium to avoid precurarization-induced neuromuscular block. J Anesth 2011 ; 25 : 200-4.

6) Donati F, et al. Vecuronium neuromuscular blockade at the diaphragm, the orbicularis oculi, and adductor pollicis muscles. Anesthesiology 1990 ; 73 : 870-5.

7) Fuchs-Buder T. 鈴木孝浩, 訳. 臨床麻酔と研究における筋弛緩モニタリング. 東京 : 真興交易医書出版部 : 2013. p. 30.

8) Ali HH, et al. Stimulus frequency in the detection of neuromuscular block in humans. Br J Anaesth 1970 ; 42 : 967-78.

9) Viby-Mogensen J, et al. Posttetanic count (PTC) : A new method of evaluating an intense nondepolarizing neuromuscular blockade. Anesthesiology 1981 ; 55 : 458-61.

10) Murphy GS, et al. Intraoperative acceleromyographic monitoring reduces the risk of residual neuromuscular blockade and adverse respiratory events in the postanesthesia care unit. Anesthesiology 2008 ; 109 : 389-98.

11) Plaud B, et al. Residual paralysis after emergence from anesthesia. Anesthesiology 2010 ; 112 : 1013-22.

12) Capron F, et al. Can acceleromyography detect low levels of residual paralysis? A probability approach to detect a mechanomyographic train-of-four ratio of 0.9. Anesthesiology 2004 ; 100 : 1119-24.

13) Kotake Y, et al. Reversal with sugammadex in the absence of monitoring did not preclude residual neuromuscular block. Anesth Analg 2013 ; 117 : 345-51.

14) Eleveld J, et al. A temporary decrease in twitch response during reversal of rocuronium-induced muscle relaxation with a small dose of sugammadex. Anesth Analg 2007 ; 104 : 582-4.

15) Suzuki T. A train-of-four ratio of 0.9 may not certify adequate recovery after sugammadex. Acta Anaesthesiol Scand 2011 ; 55 : 368-9.

P.101 掲載の参考文献

1) Khuenl-Brady K, et al. The neuromuscular blocking effects and pharmacokinetics of ORG 9426 and ORG 9616 in the cat. Anesthesiology 1990 ; 72 : 669-74.

2) Plaud B, et al. The corrugator supercilii, not the orbicularis oculi, reflects rocuronium neuromuscular blockade at the laryngeal adductor muscles. Anesthesiology 2001 ; 95 : 96-101.

3) Schultz P, et al. Onset and duration of action of rocuronium--from tracheal intubation, through intense block to complete recovery. Acta Anaesthesiol Scand 2001 ; 45 : 612-7.

4) Lowry DW, et al. Neuromuscular effects of rocuronium during sevoflurane, isoflurane, and intravenous anesthesia. Anesth Analg 1998 ; 87 : 936-40.

5) Magorian T, et al. Comparison of rocuronium, succinylcholine, and vecuronium for rapid-sequence induction of anesthesia in adult patients. Anesthesiology 1993 ; 79 : 913-8.

6) Gibson FM, at al. Quantification of train-of-four responses during recovery of block from non-depolarising muscle relaxants. Acta Anaesthesiol Scand 1987 ; 31 : 655-7.

7) Magorian T, et al. The pharmacokinetics and neuromuscular effects of rocuronium bromide in patients with liver disease. Anesth Analg 1995 ; 80 : 754-9.

8) Robertson EN, et al. Pharmacodynamics of rocuronium 0.3 mg kg (-1) in adult patients with and without renal failure. Eur J Anaesthesiol 2005 ; 22 : 929-32.

P.105 掲載の参考文献

1) 鈴木太, ほか. ベクロニウムブロマイドの臨床使用-各施設における協同研究の成績. 麻酔 1986, 35 : 100-13.

2) 日本麻酔科学会. VI 筋弛緩薬・拮抗薬. 麻酔薬および麻酔関連薬使用ガイドライン第3版. 2012. http://www.anesth.or.jp/guide/pdf/publication4-6_20121106.pdf

3) 日本麻酔科学会. IX 産科麻酔薬. 麻酔薬および麻酔関連薬使用ガイドライン第3版. 2012. http://www.anesth.or.jp/guide/pdf/publication4-9_20121106.pdf

4) Hawkins JL, et al. Vecuronium for rapid-sequence intubation for cesarean section. Anesth Analg 1990 ; 71 : 185-90.

5) Yoshida A, et al. Prolonged relaxant effects of vecuronium in patients with deliberate hypermagnesemia : Time for caution in cesarean section. J Anesth 2006 ; 20 : 33-5.

6) Fisher DM, Miller RD. Neuromuscular effects of vecuronium (ORG NC45) in infants and children during N2O, halothane anesthesia. Anesthesiology 1983 ; 58 : 519-23.

7) 日本麻酔科学会. X 小児麻酔薬. 麻酔薬および麻酔関連薬使用ガイドライン第3版. 2012. http://www.anesth.or.jp/guide/pdf/publication4-10_20121106.pdf

8) 妙中信之, ほか. 人工呼吸中の鎮静のためのガイドライン. 人工呼吸 2007 ; 24 : 146-67.

9) Khuenl-Brady KS, et al. Sugammadex provides faster reversal of vecuronium-induced neuromuscular blockade compared with neostigmine : A multicenter, randomized, controlled trial. Anesth Analg 2010 ; 110 : 64-73.

10) Puhringer FK et al. Sugammadex rapidly reverses moderate rocuronium-or vecuronium-induced neuromuscular block during sevoflurane anaesthesia : A doseresponse relationship. Br J Anaesth 2010 ; 105 : 610-9.

11) Prabhakar H, et al. Vecuronium bromide and methylprednisolone succinate are physically incompatible! J Neurosurg Anesthesiol 2008 ; 20 : 153-4.

12) Segredo V, et al. Persistent paralysis in critically ill patients after long-term administration of vecuronium. N Engl J Med 1992 : 327 : 524-8.

13) de Letter MA, et al. Risk factors for the development of polyneuropathy and myopathy in critically ill patients. Crit Care Med 2001 ; 29 : 2281-6.

14) Jurado LV, Gulbis BE. Continuous infusion versus intermittent bolus dosing of vecuronium in patients receiving therapeutic hypothermia after sudden cardiac arrest. Pharmacotherapy 2011 ; 31 : 1250-6.

P.109 掲載の参考文献

1) Benumof JL, et al. Critical hemoglobin desaturation will occur before return to an unparalyzed state following 1 mg/kg intravenous succinylcholine. Anesthesiology 1997 ; 87 : 979-82.

2) Lerman J, Chinyanga HM. The heart rate response to succinylcholine in children : A comparison of atropine and glycopyrrolate. Can Anaesth Soc J 1983 ; 30 : 377-81.

3) Kato M, et al. Comparison between in vivo and in vitro pharmacokinetics of succinylcholine in humans. J Anesth 1999 ; 13 : 189-92.

4) Wong SF, Chung F. Succinylcholine-associated postoperative myalgia. Anaesthesia 2000 ; 55 : 144-52.

5) Schreiber JU, et al. Prevention of succinylcholine-induced fasciculation and myalgia : A meta-analysis of randomized trials. Anesthesiology 2005 ; 103 : 877-84.

6) Mertes PM, et al ; Groupe d'Etudes des Reactions Anaphylactoides Peranesthesiques. Anaphylactic and anaphylactoid reactions occurring during anesthesia in France in 1999-2000. Anesthesiology 2003 ; 99 : 536-45.

7) Gronert GA. Cardiac arrest after succinylcholine : Mortality greater with rhabdomyolysis than receptor upregulation. Anesthesiology 2001 ; 94 : 523-9.

8) Thapa S, Brull SJ. Succinylcholine-induced hyperkalemia in patients with renal failure : An old question revisited. Anesth Analg 2000 ; 91 : 237-41.

P.112 掲載の参考文献

1) Sugi Y, et al. Restoration of train-of-four ratio with neostigmine after insufficient recovery with sugammadex in a patient with myasthenia gravis. A&A Case Reports 2013 ; 1 : 43-5.

2) Magorian TT, et al. Can early administration of neostigmine, in single or repeated doses, alter the course of neuromuscular recovery from a vecuronium-induced neuromuscular blockade? Anesthesiology 1990 ; 73 : 410-4.

3) Bevan DR, et al. Reversal of neuromuscular blockade. Anesthesiology 1992 ; 77 : 785-805.

4) el Hakim M. Reversal of neuromuscular blockade--effects of administration of atropine and neostigmine at different rates in man. Anaesthesiol Reanim 1987 ; 12 : 299-303.

5) Plaud B, et al. Residual paralysis after emergence from anesthesia. Anesthesiology 2010 ; 112 : 1013-22.

6) Lauretti GR, et al. A multi-center study of intrathecal neostigmine for analgesia following vaginal hysterectomy. Anesthesiology 1998 ; 89 : 913-8.

7) Jain A, et al. Analgesic efficacy of low-dose intrathecal neostigmine in combination with fentanyl and bupivacaine for total knee replacement surgery. J Anaesthesiol Clin Pharmacol 2012 ; 28 : 486-90.

8) Payne JP, et al. Neuromuscular blockade by neostigmine in anaesthetized man. Br J Anaesth 1980 ; 52 : 69-76.

9) Goldhill DR, et al. Neostigmine after spontaneous recovery from neuromuscular blockade. Effect on depth of blockade monitored with train-of-four and tetanic stimuli. Anaesthesia 1989 ; 44 : 293-9.

P.114 掲載の参考文献

1) Bevan DR, et al. Reversal of neuromuscular blockade. Anesthesiology 1992 ; 77 : 785-805.

2) el Hakim M. Reversal of neuromuscular blockade--effects of administration of atropine and neostigmine at different rates in man. Anaesthesiol Reanim 1987 ; 12 : 299-303.

P.116 掲載の参考文献

1) Cronnelly R, et al. Edrophonium : Duration of action and atropine requirement in humans during halothane anesthesia. Anesthesiology 1982 ; 57 : 261-6.

2) 中塚秀輝, 佐藤健治. 筋弛緩薬に対する拮抗の作用機序. 岩崎寛, 編. 筋弛緩薬. 東京 : 克誠堂出版 ; 2010. p. 180-93.

3) Aracava Y, et al. The molecular basis of anticholinesterase actions on nicotinic and glutamatergic synapses. Ann N Y Acad Sci 1987 ; 505 : 226-55.

4) Donati F, et al. Twitch depression and train-of-four ratio after antagonism of pancuronium with edrophonium, neostigmine, or pyridostigmine. Anesth Analg 1983 ; 62 : 314-6.

5) McCoy EP, et al. Administration of rocuronium (Org9426) by continuous infusion and its reversibility with anticholinesterases. Anaesthesia 1994 ; 49 : 940-5.

6) Bevan DR, et al. Reversal of neuromuscular blockade. Anesthesiology 1992 ; 77 : 785-805.

7) 中塚秀輝, 佐藤健治. 筋弛緩薬拮抗の至適時期とその方法. 岩崎寛, 編. 筋弛緩薬. 東京 : 克誠堂出版 ; 2010. p. 269-78.

8) Berg H, et al. Residual neuromuscular block is a risk for postoperative pulmonary complications. A prospective, randomized, and blinded study of postoperative pulmonary complications after atracurium, vecuronium and pancuronium. Acta Anaesthesiol Scand 1997 ; 41 : 1095-103.

9) 吉川弘明. 重症筋無力症の診断新たな診断方法. 脳21 2008 ; 11 : 238-42.

10) 日本医薬品集フォーラム, 監修. エドロホニウム塩化物. 日本医薬品集医療薬2015年版. 東京 : 株式会社じほう ; 2014. p. 653.

P.119 掲載の参考文献

1) Baldo BA, et al. Drug-specific cyclodextrins with emphasis on sugammadex, the neuromuscular blocker rocuronium and perioperative anaphylaxis : implications for drug allergy. Clin Exp Allergy 2011 ; 41 : 1663-78.

2) 鈴木孝浩. スガマデクス (sugammadex : Org25969, modified γ-cyclodextrin) -新しい非脱分極性筋弛緩拮抗薬. 麻酔 2006 ; 55 : 834-40.

3) Lee C, et al. Reversal of profound neuromuscular block by sugammadex administered three minutes after rocuronium : a comparison with spontaneous recovery from succinylcholine. Anesthesiology 2009 ; 110 : 1020-5.

4) Duvaldestin P, et al. A randomized, dose-response study of sugammadex given for the reversal of deep rocuronium-or vecuronium-induced neuromuscular blockade under sevoflurane anesthesia. Anesth Analg 2010 ; 110 : 74-82.

5) Suzuki T, et al. Reversibility of rocuronium-induced profound neuromuscular block with sugammadex in younger and older patients. Br J Anaesth 2011 ; 106 : 823-6.

P.121 掲載の参考文献

1) Harrison GG. Control of the malignant hyperpyrexic syndrome in MHS swine by dantrolene sodium. Br J Anaesth 1975 ; 47 : 62-5.

2) Endo M, et al. Changes in the Ca-induced Ca release mechanism in the sarcoplasmic reticulum of the muscle from a patient with malignant hyperthermia. Biomed Res 1983 ; 4 : 83-92.

3) Endo M, et al. Calcium induced release of calcium from the sarcoplasmic reticulum of skinned skeletal muscle fibres. Nature 1970 ; 228 : 34-6.

4) 菊地博達. 悪性高熱症の発症機序・検査法と治療. 日本醫事新報. 1997 ; 3812 : 11-6.

5) Paul-Pletzer K, et al. Identification of a dantrolene-binding sequence on the skeletal muscle ryanodine receptor. J Biol Chem 2002 ; 277 : 34918-23.

6) Kobayashi S, et al. Dantrolene, a therapeutic agent for malignant hyperthermia, markedly improves the function of failing cardiomyocytes by stabilizing interdomain interactions within the ryanodine receptor. J Am Coll Cardiol 2009 ; 53 : 1993-2005.

7) 市原靖子. VI. 治療治療法. 菊地博達, 編. 悪性高熱症. 東京 : 克誠堂出版 ; 2006. p. 155-8.

8) Mitchell LW, Leighton BL. Warmed diluent speeds dantrolene reconstitution. Can J Anaesth 2003 ; 50 : 127-30.

P.127 掲載の参考文献

1) De Conno E, et al. Anesthetic-induced improvement of the inflammatory response to one-lung ventilation. Anesthesiology 2009 ; 110 : 1316-26.

2) Altay O, et al. Isoflurane delays the development of early brain injury after subarachnoid hemorrhage through sphingosine-related pathway activation in mice. Crit Care Med 2012 ; 40 : 1908-13.

3) Kodama M, et al. Neonatal desflurane exposure induces more robust neuroapoptosis than do isoflurane and sevoflurane and impairs working memory. Anesthesiology 2011 ; 115 : 979-91.

4) Nyktari V, et al. Respiratory resistance during anaesthesia with isoflurane, sevoflurane, and desflurane : A randomized clinical trial. Br J Anaesth 2011 ; 107 : 454-61.

5) White PF, et al. Desflurane versus sevoflurane for maintenance of outpatient anesthesia : The effect on early versus late recovery and perioperative coughing. Anesth Analg 2009 ; 109 : 387-93.

6) Turan A, et al. The association between nitrous oxide and postoperative mortality and morbidity after noncardiac surgery. Anesth Analg 2013 ; 116 : 1026-33.

7) Ryan SM, et al. Global warming potential of inhaled anesthetics : Application to clinical use. Anesth Analg 2010 ; 111 : 92-8.

P.129 掲載の参考文献

1) 河野達郎. 脊髄後角への興奮性伝達に対する亜酸化窒素の作用. PAIN RESEARCH 2008 ; 23 : 1-9.

2) Echevarria G, et al. Nitrous oxide (N2O) reduces postoperative opioid-induced hyperalgesia after remifentanil-propofol anaesthesia in humans. Br J Anaesth 2011 ; 107 : 959-65.

3) 大路正人, ほか. 眼内長期滞留ガス (SF6, C3F8) 使用ガイドライン. 日眼会誌 2010 ; 114 : 110-5.

4) 萬家俊博. 亜酸化窒素の生き残る道. 日臨麻会誌 2013 ; 33 : 730-5.

5) Myles PS, et al. Avoidance of nitrous oxide for patients undergoing major surgery : A randomized controlled trial. Anesthesiology 2007 ; 107 : 221-31.

6) Ryan SM, Nielsen CJ. Global warming potential of inhaled anesthetics : Application to clinical use. Anesth Analg 2010 ; 111 : 92-8.

P.133 掲載の参考文献

1) Katoh T, et al. Influence of age on awakening concentrations of sevoflurane and isoflurane. Anesth Analg 1993 ; 76 : 348-52.

2) Katoh T, et al. The effect of fentanyl on sevoflurane requirements for somatic and sympathetic responses to surgical incision. Anesthesiology 1999 ; 90 : 398-405.

3) Campagna JA, et al. Mechanisms of actions of inhaled anesthetics. N Engl J Med 2003 ; 348 : 2110-24.

4) Kharasch ED, et al. Clinical sevoflurane metabolism and disposition. I. Sevoflurane and metabolite pharmacokinetics. Anesthesiology 1995 ; 82 : 1369-78.

5) Holaday DA, Smith FR. Clinical characteristics and biotransformation of sevoflurane in healthy human volunteers. Anesthesiology 1981 ; 54 : 100-6.

6) De Hert SG, et al. Sevoflurane but not propofol preserves myocardial function in coronary surgery patients. Anesthesiology 2002 ; 97 : 42-9.

7) De Hert S, et al. A comparison of volatile and non volatile agents for cardioprotection during on-pump coronary surgery. Anaesthesia 2009 ; 64 : 953-60.

8) Julier K, et al. Preconditioning by sevoflurane decreases biochemical markers for myocardial and renal dysfunction in coronary artery bypass graft surgery : A doubleblinded, placebo-controlled, multicenter study. Anesthesiology 2003 ; 98 : 1315-27.

9) Rooke GA, et al. The effect of isoflurane, halothane, sevoflurane, and thiopental/nitrous oxide on respiratory system resistance after tracheal intubation. Anesthesiology 1997 ; 86 : 1294-9.

10) Ti LK, et al. Comparison of sevoflurane with propofol for laryngeal mask airway insertion in adults. Anesth Analg 1999 ; 88 : 908-12.

11) Epstein RH, et al. Lessin JB. High concentration versus incremental induction of anesthesia with sevoflurane in children : a comparison of induction times, vital signs, and complications. J Clin Anesth 1998 ; 10 : 41-5.

12) 鈴木昭広. セボフルラン吸入法 (VIMA) の各種方法とその特徴. 並木昭義, ほか編. 今日から実践できるVIMA. 真興交易 (株) 医書出版部 ; 2003. p. 34-57.

13) Constant I, et al. Sevoflurane and epileptiform EEG changes. Paediatr Anaesth 2005 ; 15 : 266-74.

14) Cravero J, et al. Emergence agitation in paediatric patients after sevoflurane anaesthesia and no surgery : A comparison with halothane. Paediatr Anaesth 2000 ; 10 : 419-24.

15) Kim MS, et al. Comparison of propofol and fentanyl administered at the end of anaesthesia for prevention of emergence agitation after sevoflurane anaesthesia in children. Br J Anaesth 2013 ; 110 : 274-80.

P.136 掲載の参考文献

1) Cameron CB, et al. The minimum anesthetic concentration of isoflurane in children. Anesth Analg 1984 ; 63 : 418-20.

2) Koerner IP, Brambrink AM. Brain protection by anesthetic agents. Curr Opin Anaesthesiol 2006 ; 19 : 481-6.

3) Miller RD, ed. Miller's Anesthesia. 6th ed. Philadelphia : Elsevier, Churchill Livingstone ; 2005. Pagel PS, et al. 心血管系への薬理作用. 武田純三, 監修, 稲田英一, ほか監訳. ミラー麻酔科学. 原著第6版. 東京 : メディカル・サイエンス・インターナショナル ; 2007. p. 153-62.

4) Van Rompaey N, Barvais L. Clinical application of the cardioprotective effects of volatile anaesthetics : CON--total intravenous anaesthesia or not total intravenous anaesthesia to anaesthetize a cardiac patient? Eur J Anaesthesiol 2011 ; 28 : 623-7.

5) 大山晃弘. 気管支喘息重積発作に対する揮発性麻酔薬の比較. ICU&CCU 1998 ; 22 : 101-6.

P.140 掲載の参考文献

1) Ishizawa Y. Special article : General anesthetic gases and the global environment. Anesth Analg 2011 ; 112 : 213-7.

2) Berry PD, et al. Severe carbon monoxide poisoning during desflurane anesthesia. Anesthesiology 1999 ; 90 : 613-6.

3) Ryan S, Sherman J. Sustainable anesthesia. Anesth Analg 2012 ; 114 : 921-3.

4) Feldman JM. Managing fresh gas flow to reduce environmental contamination. Anesth Analg 2012 ; 114 : 1093-101.

5) 木山秀哉. EtC-スムーズで安全な吸入麻酔を提供する新テクノロジー. 日本臨床麻酔学会誌 2013 ; 33 : 563-71.

6) Baum J, et al. Niedrigflusnarkosen mit Desfluran. [Low-flow anesthesia with desflurane]. Der Anaesthesist 1997 ; 46 : 287-93.

7) Avidan MS, et al. Prevention of intraoperative awareness in a high-risk surgical population. N Engl J Med 2011 ; 365 : 591-600.

8) 木山秀哉. 徹底分析シリーズデスフルラン 1 デスフルランの物理化学. LiSA 2013 ; 20 : 22-8.

9) 木山秀哉. デスフルランの物理化学. 臨床麻酔 2013 ; 37 : 460-8.

P.147 掲載の参考文献

1) Liu SS, Joseph RS. Local anesthetics. In : Barash PG, et al, eds. Clinical Anesthesia. 5th ed. Philadelphia : Lippincott Williams & Wilkins ; 2006. p. 453-71.

2) Berde CB, Strichartz GR. Local anesthetics. In : Miller RD, ed. Miller's Anesthesia. 7th ed. Philadelphia : Churchill Livingstone ; 2010. p. 913-39.

3) 紫藤明美. 局所麻酔薬の選択. 佐倉伸一, 編. 周術期超音波ガイド下神経ブロック. 東京 : 真興交易医書出版部 ; 2011. p. 108-34.

4) Polly LS, et al. Relative analgesic potencies of ropivacaine and bupivacaine for epidural analgesia in labor : Implications for therapeutic indexes. Anesthesiology 1999 ; 90 : 944-50.

5) Dalens BJ. Regional anesthesia in children. Miller RD, ed. Miller's Anesthesia. 7th ed. Philadelphia : Churchill Livingstone ; 2010. p. 2519-57.

6) Carpenter RL, Mackey DC. Local anesthetics. In : Barash PG, et al, eds. Clinical Anesthesia. 2nd ed. Philadelphia : Lippincott Williams & Wilkins ; 1992. p. 509-41.

7) 高崎眞弓. 薬液の選択. 硬膜外鎮痛と麻酔-理論から手技の実際まで. 東京 : 文光堂 ; 2009. p. 25-33.

8) Kato N, et al. Serum concentration of lidocaine after transversus abdominis plane block. J Anesth 2009 ; 23 : 298-300.

9) Griffiths JD, et al. Plasma ropivacaine concentrations after ultrasound-guided transversus abdominis plane block. Br J Anaesth 2010 ; 105 : 853-6.

10) Neal JM, et al. ASRA practice advisory on local anesthetic systemic toxicity. Reg Anesth Pain Med 2010 ; 35 : 152-61.

11) Lange DB, et al. Use of intravenous lipid emulsion to reverse central nervous system toxicity of an iatrogenic local anesthetic overdose in a patient on peritoneal dialysis. Ann Pharmacother 2012 ; 46 : e37.

12) Neal JM, et al. American Society of Regional Anesthesia and Pain Medicine checklist for managing local anesthetic systemic toxicity : 2012 version. Reg Anesth Pain Med 2012 ; 37 : 16-8.

P.150 掲載の参考文献

1) Yokoyama M, et al. Comparison of plasma lidocaine concentrations after injection of a fixed small volume in the stellate ganglion, the lumbar epidural space, or a single intercostal nerve. Anesth Analg 1998 ; 87 : 112-5.

2) Bernards CM, Kopacz DJ. Effect of epinephrine on lidocaine clearance in vivo : A microdialysis study in humans. Anesthesiology 1999 ; 91 : 962-8.

3) Werdehausen R, et al. Lidocaine metabolites inhibit glycine transporter 1 : A novel mechanism for the analgesic action of systemic lidocaine? Anesthesiology 2012 ; 116 : 147-58.

4) Eberhart LH, et al. Transient neurologic symptoms after spinal anesthesia. A quantitative systematic overview (meta-analysis) of randomized controlled studies. Anaesthesist 2002 ; 51 : 539-46.

P.152 掲載の参考文献

1) 藤原祥裕. 局所麻酔薬の基礎と臨床-末梢神経ブロックを中心として. Anesthesia 21 Century 2012 ; 14 : 68-71.

2) 横山正尚. 局所麻酔薬. レジデント 2013 ; 6 : 44-51.

3) Strichartz GR, Berde CB. Local anesthetics. In : Miller RD, ed. Miller's Anesthesia. 6th ed. Philadelphia : Churchill Livingstone ; 2005. p. 573-603.

4) 日本麻酔科学会安全委員会医薬品適正評価対策ワーキンググループ, 編. 局所麻酔薬. 麻酔薬および麻酔関連薬使用ガイドライン第3版. 2009. p. 129-30.

5) Laur JJ, et al. Triple-blind randomized clinical trial of time until sensory change using 1.5% mepivacaine with epinephrine, 0.5% bupivacaine, or an equal mixture of both for infraclavicular block. Reg Anesth Pain Med 2012 ; 37 : 28-33.

6) Cuvillon P, et al. A comparison of the pharmacodynamics and pharmacokinetics of bupivacaine, ropivacaine (with epinephrine) and their equal volume mixtures with lidocaine used for femoral and sciatic nerve blocks : A double-blind randomized study. Anesth Analg 2009 ; 108 : 641-9.

P.155 掲載の参考文献

1) 大澤正巳, ほか. 長時間作用性局所麻酔薬塩酸ロピバカイン (NA-001) 10 mg/ml 注射液による硬膜外麻酔の検討. 臨床医薬 1999 ; 15 : 1175-89.

2) 山本健, ほか. 長時間作用性局所麻酔薬塩酸ロピバカイン (NA-001) による腕神経叢ブロックの至適投与量の検討-第II相試験. 臨床医薬 1999 ; 15 : 1137-54.

3) Bader AM, et al. Comparison of bupivacaine-and ropivacaine-induced conduction blockade in the isolated rabbit vagus nerve. Anesth Analg 1989 ; 68 : 724-7.

4) Ohmura S, et al. Systemic toxicity and resuscitation in bupivacaine-, levobupivacaine-, or ropivacaine-infused rats. Anesth Analg 2001 ; 93 : 743-8.

5) 大澤正巳, ほか. 長時間作用性局所麻酔薬塩酸ロピバカイン (NA-001) 7.5 mg/ml 注射液による硬膜外麻酔の臨床的検討-塩酸ブピバカインを対照薬とした二重盲検群間比較試験. 臨床医薬 1999 ; 15 : 1205-28.

6) Knudsen K, et al. Central nervous and cardiovascular effects of i.v.infusions of ropivacaine, bupivacaine and placebo in volunteers. Br J Anaesth 1997 ; 78 : 507-14.

7) Griffiths JD, et al. Plasma ropivacaine concentrations after ultrasound-guided transversus abdominis plane block. Br J Anesth 2010 ; 105 : 853-6.

8) Behnke H, et al. Plasma concentration of ropivacaine after intercostal blocks for videoassisted thoracic surgery. Br J Anaesth 2002 ; 89 : 251-3.

9) Neal M, et al. ASRA practice advisory on local anesthetic systemic toxicity. Reg Anesth Pain Med 2010 ; 35 : 152-61.

P.158 掲載の参考文献

1) Albright GA. Cardiac arrest following regional anesthesia with etidocaine or bupivacaine. Anesthesiology 1979 ; 51 : 285-7.

2) Santos AC, et al. Local anesthetics and opioids. In : Chestnut DH, et al, ed. Obstetric Anesthesia : Principles and Practice. 4th ed. Philadelphia : Mosby Elsevier ; 2008 : p. 247-75.

3) Strichartz GR, et al. Local anesthesia. In : Miller RD, ed. Miller's Anesthesia. 6th ed. Philadelphia : Churchill Livingstone ; 2005. 武田純三, 監修. 稲田英一, ほか監訳. 局所麻酔薬. ミラー麻酔科学. 原著第6版. 東京 : メディカル・サイエンス・インターナショナル ; 2007. p. 453-76.

4) Burm AG, et al. Epidural anesthesia with lidocaine and bupivacaine : Effects of epinephrine on the plasma concentration profiles. Anesth Analg 1986 ; 65 : 1281-4.

5) Sinclair CJ, Scott DB. Comparison of bupivacaine and etidocaine in extradural blockade. Br J Anaesth 1984 ; 56 : 147-53.

6) Dillane D, Finucane BT. Local anesthetic systemic toxicity. Can J Anaesth 2010 ; 57 : 368-80.

7) Rosenblatt MA, et al. Successful use of a 20% lipid emulsion to resuscitate a patient after a presumed bupivacaine-related cardiac arrest. Anesthesiology 2006 ; 105 : 217-8.

8) Portillo J, et al. Safety of liposome extended-release bupivacaine for postoperative pain control. Front Pharmacol 2014 ; 5 : 90. 1-6.

9) Pacira Pharmaceuticals, Inc. Web site. http://www.exparel.com/how-to-use/aboutdepofoam.shtml

P.161 掲載の参考文献

1) 布施谷仁志, 川真田樹人. レボブピバカイン. 臨床麻酔 2012 ; 36 : 345-52.

2) Crews JC, et al. A comparison of the analgesic efficacy of 0.25 % levobupivacaine combined with 0.005% morphine, 0.25% levobupivacaine alone, or 0.005% morphine alone for the management of postoperative pain in patients undergoing major abdominal surgery. Anesth Analg 1999 ; 89 : 1504-9.

3) Dernedde M, et al. Continuous epidural infusion of large concentration/small volume versus small concentration/large volume of levobupivacaine for postoperative analgesia. Anesth Analg 2003 ; 96 : 796-801.

4) Kopacz DJ, et al. A comparison levobupivacaine 0.125%, fentanyl 4 microg/mL, or their combination for the patient-controlled epidural analgesia after major orthopedic surgery. Anesth Analg 1999 ; 89 : 1497-503.

5) Murdock JA, et al. The efficacy and safety of three concentrations of levobupivacaine administered as a continuous epidural infusion in patients undergoing orthopedic surgery. Anesth Analg 2002 ; 94 : 438-44.

6) Valenzuela C, et al. Stereoselective block of cardiac sodium channels by bupivacaine in guinea pig ventricular myocytes. Circulation 1995 ; 92 : 3014-24.

7) Valenzuela C, et al. Stereoselective block of a human cardiac potassium channel (Kv1.5) by bupivacaine enantiomers. Biophys J 1995 ; 69 : 418-27.

8) Burlacu CL, Buggy DJ. Update local anesthetics : Focus on levobupivacaine. Ther Clin Risk Manag 2008 ; 4 : 381-92.

9) Chang DH, et al. Tolerability of large-dose intravenous levobupivacaine in sheep. Anesth Analg 2000 ; 91 : 671-9.

10) Bardsley H, et al. A comparison of the cardiovascular effects of levobupivacaine and rac-bupivacaine following intravenous administration to healthy volunteers. Br J Clin Pharmacol 1998 ; 46 : 245-9.

11) Kopacz DJ, Allen HW. Accidental intravenous levobupivacaine. Anesth Analg 1999 ; 89 : 1027-9.

12) Pirotta D, Sprigge J. Convulsions following axillary brachial plexus blockade with levobupivacaine. Anaesthesia 2002 ; 57 : 1187-9.

13) Salomaki TE, et al. Successful resuscitation after cardiovascular collapse following accidental intravenous infusion of levobupivacaine during general anesthesia. Anesthesiology 2005 ; 103 : 1095-6.

P.166 掲載の参考文献

1) 医薬品インタビューフォーム. 局所麻酔剤テトカイン(R) 注用20 mg「杏林」. 2014年3月改訂 (第9版). 杏林製薬株式会社.

2) Strichartz GR, et al. Fundamental properties of local anesthetics. II. Measured octanol : Buffer partition coefficients and pKa values of clinically used drugs. Anesth Analg 1990 ; 71 : 158-70.

3) Kim JA, Ahn HJ. Hypobaric spinal anesthesia with 0.2% tetracaine for total joint hip arthroplasty. Can J Anesth 2005 ; 52 : 958-62.

4) Ready LB, et al. Neurotoxicity of intrathecal local anesthetics in rabbits. Anesthesiology 1985 ; 63 : 364-70.

5) 鈴木太, ほか. 脊椎麻酔におけるAJ-007 (塩酸ブピバカイン) の臨床試験-等比重および高比重製剤の臨床用量の検討. 麻酔 1998 ; 47 : 447-65.

6) Solakovic N. Comparison of hemodynamic effects of hyperbaric and isobaric bupivacaine in spinal anesthesia. Med Arh 2010 ; 64 : 11-4.

7) アストラゼネカ株式会社社内資料 (ブピバカインの脊髄クモ膜下腔投与後の静脈血液中濃度, 2000).

8) Arzola C, Wieczorek PM. Efficacy of low-dose bupivacaine in spinal anaesthesia for Caesarean delivery : Systematic review and meta-analysis. Br J Anaesth 2011 ; 107 : 308-18.

P.171 掲載の参考文献

1) American Society of Anesthesiologists Task Force on Acute Pain Management. Practice guidelines for acute pain management in the perioperative setting : An updated report by the American Society of Anesthesiologists Task Force on Acute Pain Management. Anesthesiology 2012 ; 116 : 248-73.

2) Derry S, Moore RA. Single dose oral celecoxib for acute postoperative pain in adults. Cochrane Database Syst Rev 2013 Oct 22 ; 10 : CD004233.

3) Takada M, et al. Intravenous flurbiprofen axetil can stabilize the hemodynamic instability due to mesenteric traction syndrome--Evaluation with continuous measurement of the systemic vascular resistance index using a FloTrac(R) sensor. J Cardiothorac Vasc Anesth 2013 ; 27 : 696-702.

4) Ong CKS, et al. Combining paracetamol (acetaminophen) with nonsteroidal antiinflammatory drugs : A qualitative systematic review of analgesic efficacy for acute postoperative pain. Anesth Analg 2010 ; 110 : 1170-9.

5) Schmidt PC, et al. Perioperative gabapentinoids : Choice of agent, dose, timing, and effects on chronic postsurgical pain. Anesthesiology 2013 ; 119 : 1215-21.

6) Blaudszun G, et al. Effect of perioperative systemic α2 agonists on postoperative morphine consumption and pain intensity : Systematic review and meta-analysis of randomized controlled trials. Anesthesiology 2012 ; 116 : 1312-22.

7) Lambert P, et al. Clonidine premedication for postoperative analgesia in children. Cochrane Database Syst Rev 2014 Jan 28 ; 1 : CD009633.

8) Bell RF, et al. Perioperative ketamine for acute postoperative pain. Cochrane Database Syst Rev 2006 Jan 25 ; (1) : CD004603.

P.175 掲載の参考文献

1) Chandrasekharan NV, Simmons DL. The cyclooxygenases. Genome Biol 2004 ; 5 : 241.

2) Rao P, Knaus EE. Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs) : Cyclooxygenase (COX) inhibition and beyond. J Pharm Pharm Sci 2008 ; 11 : 81s-110s.

3) Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 1998 ; 104 : 413-21.

4) Fries JF. Measuring the quality of life in relation to arthritis therapy. Postgrad Med 1983 ; Spec No : 49-56.

5) Cuzzolin L, et al. NSAID-induced nephrotoxicity from the fetus to the child. Drug Saf 2001 ; 24 : 9-18.

P.178 掲載の参考文献

1) Narita M, et al. Role of interleukin-1β and tumor necrosis factor-α-dependent expression of cyclooxygenase-2 mRNA in thermal hyperalgesia induced by chronic inflammation in mice. Neuroscience 2008 ; 152 : 477-86.

2) Simmons DL, et al. Cyclooxygenase isozymes : the biology of prostaglandin synthesis and inhibition. Pharmacol Rev 2004 ; 56 : 387-437.

3) Chen LC, et al. Systematic review of the analgesic efficacy and tolerability of COX-2 inhibitors in post-operative pain control. J Clin Pharm Ther 2004 ; 29 : 215-29.

4) White PF, et al. The effects of oral ibuprofen and celecoxib in preventing pain, improving recovery outcomes and patient satisfaction after ambulatory surgery. Anesth Analg 2011 ; 112 : 323-9.

5) Wallace JL, et al. Cyclooxygenase-inhibiting nitric oxide donators for osteoarthritis. Trends Pharmacol Sci 2009 ; 30 : 112-7.

6) Borhade N, et al. NO-NSAIDs. Part 3 : Nitric oxide-releasing prodrugs of non-steroidal anti-inflammatory drugs. Chem Pharm Bull (Tokyo) 2012 ; 60 : 465-81.

7) Warner TD, Mitchell JA. Cyclooxygenases : New forms, new inhibitors, and lessons from the clinic. FASEB J 2004 ; 18 : 790-804.

8) McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase : A systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006 ; 296 : 1633-44.

9) Boers M. NSAIDS and selective COX-2 inhibitors : Competition between gastroprotection and cardioprotection. Lancet 2001 ; 357 : 1222-3.

P.180 掲載の参考文献

1) Toussaint K, et al. What do we (not) know about how paracetamol (acetaminophen) works? J Clin Pharm Ther. 2010 ; 35 : 617-38.

2) 伊吹京秀. アセトアミノフェン. 山本達郎, 編. 痛みの薬物治療. 東京 : 文光堂 ; 2013, p. 177-80.

3) Chandrasekharan NV, et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs : Cloning, structure, and expression. Proc Natl Acad Sci U S A 2002 ; 99 : 13926-31.

4) Toms L, et al. Single dose oral paracetamol (acetaminophen) for postoperative pain in adults. Cochrane Database Syst Rev. 2008 ; (4) : CD004602.

5) Moore RA, et al. Minimum efficacy criteria for comparisons between treatments using individual patient meta-analysis of acute pain trials : examples of etoricoxib, paracetamol, ibuprofen, and ibuprofen/paracetamol combinations after third molar extraction. Pain 2011 ; 152 : 982-9.

6) Prior MJ, et al. Efficacy and safety of acetaminophen and naproxen in the treatment of tension-type headache. A randomized, double-blind, placebo-controlled trial. Cephalalgia 2002 ; 22 : 740-8.

7) Derry S, Moore RA. Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev 2013 30 ; 4 : CD008040

8) Wienecke T, Gotzsche PC. Paracetamol versus nonsteroidal anti-inflammatory drugs for rheumatoid arthritis. Cochrane Database Syst Rev 2004 ; (1) : CD003789.

9) Casazza BA.Diagnosis and treatment of acute low back pain. Am Fam Physician 2012 ; 85 : 343-50.

10) Dagenais S, et al. Synthesis of recommendations for the assessment and management of low back pain from recent clinical practice guidelines. Spine J 2010 ; 10 : 514-29.

11) Beebe FA, et al. A clinical and pharmacologic review of skeletal muscle relaxants for musculoskeletal conditions. Am J Ther 2005 ; 12 : 151-71.

12) McNicol E, et al. NSAIDS or paracetamol, alone or combined with opioids, for cancer pain. Cochrane Database Syst Rev 2005 ; (1) : CD005180.

P.184 掲載の参考文献

1) Stewart BH, et al. A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Pharm Res 1993 ; 10 : 276-81.

2) Su TZ, et al. Mediation of highly concentrative uptake of pregabalin by L-type amino acid transport in Chinese hamster ovary and Caco-2 cells. J Pharmacol Exp Ther 2005 ; 313 : 1406-15.

3) Dahl JB, et al. 'Protective premedication' : An option with gabapentin and related drugs? A review of gabapentin and pregabalin in in the treatment of postoperative pain. Acta Anaesthesiol Scand 2004 ; 48 : 1130-6.

4) Dauri M, et al. Gabapentin and pregabalin for the acute post-operative pain management. A systematic-narrative review of the recent clinical evidences. Curr Drug Targets 2009 ; 10 : 716-33.

5) Straube S, et al. Single dose oral gabapentin for established acute postoperative pain in adults. Cochrane Database Syst Rev 2010 May 12 ; (5) : CD008183.

6) Macrae WA, Davies HTO. Chronic postsurgical pain. In : Crombie IK, et al, eds. Epidemiology of Pain. Seattle : IASP Press ; 1999. p. 125-42.

7) Clarke H, et al. The prevention of chronic postsurgical pain using gabapentin and pregabalin : A combined systematic review and meta-analysis. Anesth Analg 2012 ; 115 : 428-42.

8) Chaparro LE, et al. Pharmacotherapy for the prevention of chronic pain after surgery in adults. Cochrane Database Syst Rev 2013 Jul 24 ; 7 : CD008307.

3章全身管理薬

P.191 掲載の参考文献

1) Brodde OE, Michel MC. Adrenergic and muscarinic receptors in the human heart. Pharmacol Rev 1999 ; 51 : 651-90.

2) Thomas SS, Nohria A. Hemodynamic classifications of acute heart failure and their clinical application : -An update-. Circ J 2012 ; 76 : 278-86.

3) Bocchi EA, et al. I Latin American Guidelines for the Assessment and Management of Decompensated Heart Failure. Arq Bras Cardiol 2005 ; 85 (Suppl 3) : 49-94 ; 1-48.

4) Fares WH. Management of acute decompensated heart failure in an evidence-based era : What is the evidence behind the current standard of care? Heart Lung 2008 ; 37 : 173-8.

5) 日本循環器学会, ほか. 急性心不全治療ガイドライン (2011年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2011_izumi_h.pdf

6) 日本集中治療医学会Sepsis Registry委員会, 編. 日本版敗血症診療ガイドライン. 2012. http://www.jsicm.org/pdf/SepsisJapan2012.pdf

7) 外須美夫. 麻酔・集中治療のための呼吸・循環のダイナミズム. 東京 : 真興交易医書出版部 ; 2011.

8) Majure DT, Teerlink JR. Update on the Management of Acute Decompensated Heart Failure. Curr Treat Options Cardiovasc Med 2011 ; 13 : 570-85.

9) Peterson JW, Felker GM. Inotropes in the management of acute heart failure. Crit Care Med 2008 ; 36 (1 Suppl) : S106-11.

10) Veeser M, et al. Vasopressors for the management of hypotension after spinal anesthesia for elective caesarean section. Systematic review and cumulative metaanalysis. Acta Anaesthesiol Scand 2012 ; 56 : 810-6.

11) Heesen M, et al. Prophylactic phenylephrine for caesarean section under spinal anaesthesia : Systematic review and meta-analysis. Anaesthesia 2014 ; 69 : 143-65.

12) Licker M, et al. Clinical review : Management of weaning from cardiopulmonary bypass after cardiac surgery. Ann Card Anaesth 2012 ; 15 : 206-23.

P.194 掲載の参考文献

1) Bengel FM. Imaging targets of the sympathetic nervous system of the heart : Translational considerations. J Nucl Med 2011 ; 52 : 1167-70.

2) Kobayashi S, et al. The sympathomimetic actions of l-ephedrine and d-pseudoephedrine : Direct receptor activation or norepinephrine release? Anesth Analg 2003 ; 97 : 1239-45.

3) Lin CS, et al. Intravenous lidocaine and ephedrine, but not propofol, suppress fentanylinduced cough. Can J Anaesth 2004 ; 51 : 654-9.

4) Wilkimson GR, Beckett AH. Absorption metabolism and excretion of the ephedrines in man. I. The influence of urinary pH and urine volume output. J Pharmacol Exp Ther 1968 ; 162 : 139-47.

5) 麻酔薬および麻酔関連薬使用ガイドライン第3版 VIII 循環作動薬. 日本麻酔科学会. http://www.anesth.or.jp/guide/pdf/publication4-8_20121106.pdf

6) 貫文三郎. 吉利和, ほか編. 臨床薬理学大系第6巻アレルギー治療薬-呼吸系に作用する薬物. 東京 : 中山書店 ; 1969. p. 331.

7) Wahl A, et al. Coronary artery spasm and non-Q-wave myocardial infarction following intravenous ephedrine in two healthy women under spinal anaesthesia. Br J Anaesth 2002 ; 89 : 519-23.

8) Hirabayashi Y, et al. Coronary artery spasm after ephedrine in a patient with high spinal anesthesia. Anesthesiology 1996 ; 84 : 221-4.

9) Veeser M, et al. Vasopressors for the management of hypotension after spinal anesthesia for elective caesarean section. Systematic review and cumulative metaanalysis. Acta Anaesthesiol Scand 2012 ; 56 : 810-6.

P.196 掲載の参考文献

1) Sessler DI, et al. Hospital stay and mortality are increased in patients having a "triple low" of low blood pressure, low bispectral index, and low minimum alveolar concentration of volatile anesthesia. Anesthesiology 2012 ; 116 : 1195-203.

2) Heesen M, et al. Prophylactic phenylephrine for caesarean section under spinal anaesthesia : systematic review and meta-analysis. Anaesthesia 2014 ; 69 : 143-65.

3) Habib AS. A review of the impact of phenylephrine administration on maternal hemodynamics and maternal and neonatal outcomes in women undergoing cesarean delivery under spinal anesthesia. Anesth Analg 2012 ; 114 : 377-90.

P.198 掲載の参考文献

1) De Backer D, et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 2010 ; 362 : 779-89.

2) Kellum JA, M Decker J. Use of dopamine in acute renal failure : A meta-analysis. Crit Care Med 2001 ; 29 : 1526-31.

P.200 掲載の参考文献

1) Lupei MI, Mann HJ. Vasoactive drug use in the intensive care unit : A pressing clinical decision. TMJ 2007 ; 57 : 6-15.

2) Fellahi JL, et al. Perioperative use of dobutamine in cardiac surgery and adverse cardiac outcome : Propensity-adjusted analyses. Anesthesiology 2008 ; 108 : 979-87.

P.203 掲載の参考文献

1) 光畑裕正. 全身麻酔中のアナフィラキシー. 日臨麻会誌 2012 ; 32 : 479-87.

2) 日本麻酔科学会. 麻酔薬および麻酔関連薬使用ガイドライン第3版 (第2訂) VIII 循環作動薬アドレナリン. 2012. p. 188.

P.205 掲載の参考文献

1) Mason ST, et al. Brain noradrenaline and anaesthesia : Behavioural and electrophysiological evidence. Neuroscience 1983 ; 10 : 177-85.

2) De Backer D, et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 2010 ; 362 : 779-89.

3) Claude M, et al. Effect of norepinephrine on the outcome of septic shock. Crit Care Med 2000 ; 28 : 2758-65.

4) Sakr Y, et al. Does dopamine administration in shock influence outcome? Results of the Sepsis Occurrence in Acutely Ill Patients (SOAP) Study. Crit Care Med 2006 ; 34 : 589-97.

P.208 掲載の参考文献

1) Westfall TC, Westfall DP. Adrenergic agonists and antagonists. In : Brunton LL, ed. Goodman and Gilman's the Pharmacological Basis of Therapeutics. 12th ed. New York : McGraw-Hill ; 2011. p. 277-333.

2) Stowe DF, Ebert TJ. Sympathomimetic and sympatholytic drugs. In : Evers AS, et al, eds. Anesthetic Pharmacology. 2nd ed. Cambridge : Cambridge University Press ; 2011. p. 648-65.

3) Shanewise JS, Kaplan JA. Discontinuing Cardiopulmonary Bypass. In : Kaplan JA, et al, eds. Kaplan's Cardiac Anesthesia : The Echo Era. 6th ed. Missouri : Elsevier Saunders ; 2011. p. 992-1008.

P.211 掲載の参考文献

1) Levy JH, et al. Postoperative cardiovascular management. In : Kaplan JA, et al, eds. Kaplan's Cardiac Anesthesia : The Echo Era. 6th ed. Missouri : Elsevier Saunders ; 2011. p. 1025-45.

2) 垣花泰之. ホスホジエステラーゼ III (PDE III) 阻害薬. Anesthesia 21 Century 2008 ; 10 : 32-40.

3) 趙成三. ホスホジエステラーゼ III 阻害薬. 心血管作動薬の使用法-薬力学と薬物動態を踏まえて. 土田英昭, 編. 心血管作動薬. 東京 : 克誠堂 ; 2013. p. 204-19.

4) 坪川恒久. 心血管作動薬ホスホジエステラーゼ III 阻害薬. 薬物動態から見た心血管作動薬-最適な投与法とは. 土田英昭, 編. 心血管作動薬. 東京 : 克誠堂 ; 2013. p. 314-26.

5) Cuffe MS, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure : A randomized controlled trial. JAMA 2002 ; 287 : 1541-7.

P.218 掲載の参考文献

1) Wallin JD, et al. Intravenous nicardipine for the treatment of severe hypertension. A double-blind, placebo-controlled multicenter trial. Arch Intern Med 1989 ; 149 : 2662-9.

2) Koga M, et al. Nationwide survey of antihypertensive treatment for acute intracerebral hemorrhage in Japan. Hypertens Res 2009 ; 32 : 759-64.

3) Shinohara Y, et al. III. Intracerebral Hemorrhage. J Stroke Cerebrovasc Dis 2011 ; 20 : S74-99.

4) Morgenstern LB, et al. Guidelines for the management of spontaneous intracerebral hemorrhage : A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2010 ; 41 : 2108-29.

5) Steiner T, et al. Recommendations for the management of intracranial haemorrhage-part I : Spontaneous intracerebral haemorrhage. Cerebrovasc Dis 2006 ; 22 : 294-316.

6) Koga M, et al. Systolic blood pressure lowering to 160 mmHg or less using nicardipine in acute intracerebral hemorrhage : A prospective, multicenter, observational study (the Stroke Acute Management with Urgent Risk-factor Assessment and Improvement-Intracerebral Hemorrhage study). J Hypertens 2012 ; 30 : 2357-64.

7) Holbrook RH Jr, et al. Ovine fetal cardiorespiratory response to nicardipine. Am J Obstet Gynecol 1989 ; 161 : 718-21.

8) Hersey SL, et al. Nicardipine versus nitroprusside for controlled hypotension during spinal surgery in adolescents. Anesth Analg 1997 ; 84 : 1239-44.

P.220 掲載の参考文献

1) Bristow MR, et al. Tissue response selectivity of calcium antagonists is not due to heterogeneity of [3H] -nitrendipine binding sites. Br J Pharmacol 1984 ; 82 : 309-20.

2) Cho JE, et al. Effect of nicardipine on renal function after robot-assisted laparoscopic radical prostatectomy. Urology 2009 ; 73 : 1056-60.

3) Huh H, et al. Effect of nicardipine on renal function following robot-assisted laparoscopic radical prostatectomy in patients with pre-existing renal insufficiency. J Int Med Res 2014 ; 42 : 427-35.

4) Tanaka T, et al. Blockade of calcium influx through L-type calcium channels attenuates mitochondrial injury and apoptosis in hypoxic renal tubular cells. J Am Soc Nephrol 2004 ; 15 : 2320-33.

P.222 掲載の参考文献

1) 柳澤輝行, ほか. 電位依存性Ca2+ チャネルの分子薬理学とCa拮抗薬の差異化. 齋藤宗靖, 編. 循環器病の薬物療法. 東京 : メジカルビュー社 ; 2006. p. 188-99.

2) Wijeysundera DN, Beattie WS. Calcium channel blockers for reducing cardiac morbidity after noncardiac surgery : A meta-analysis. Anesth Analg 2003 ; 97 : 634-41.

3) Matsumoto K, et al. Effects of ultrasonic skeletonization on internal thoracic and gastroepiploic arteries for coronary artery bypass grafting. Eur J Cardiothorac Surg 2006 ; 30 : 592-6.

4) Kim JY, et al. Effect of diltiazem on kidney function during laparoscopic surgery. Surg Endosc 2009 ; 23 : 1785-90.

5) Guns PJ, et al. The electro-mechanical window in anaesthetized guinea pigs : A new marker in screening for Torsade de Pointes risk. Br J Pharmacol 2012 ; 166 : 689-701.

P.225 掲載の参考文献

1) GISSI-3 : Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. Lancet 1994 ; 343 : 1115-22.

2) ISIS-4 : A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet 1995 ; 345 : 669-85.

3) Ishikawa K, et al. Long-term nitrate treatment increases cardiac events in patients with healed myocardial infarction. Secondary Prevention Group. Jpn Circ J 1996 ; 60 : 779-88.

4) Kanamasa K, et al. Chronic use of continuous dosing of long-term nitrates does not prevent cardiac events in patients with severe acute myocardial infarction. Cardiology 2000 ; 94 : 139-45.

5) Chen Z, et al. Identification of the enzymatic mechanism of nitroglycerin bioactivation. Proc Natl Acad Sci U S A 2002 ; 99 : 8306-11.

6) 木村剛, ほか. 非ST 上昇型急性冠症候群の診療に関するガイドライン (2012年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2012_kimura_h.pdf

7) Fleisher LA, et al. ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery : A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). Circulation 2007 ; 116 : e418-500.

8) 日本麻酔科学会. 麻酔薬および麻酔関連薬使用ガイドライン第3版. 2012. p. 324-7.

9) 社会保険診療報酬支払基金. 審査情報提供事例について. 平成23年9月. http://www.ssk.or.jp/shinsajoho/teikyojirei/files/jirei290.pdf

10) 日本産科婦人科学会, 日本産婦人科医会. 産婦人科診療ガイドライン-産科編 2011. p. 188-90. http://www.jsog.or.jp/activity/pdf/gl_sanka_2011.pdf

11) Munzel T, et al. More answers to the still unresolved question of nitrate tolerance. Eur Heart J 2013 ; 34 : 2666-73.

12) Mackenzie IS, et al. Aldehyde dehydrogenase 2 plays a role in the bioactivation of nitroglycerin in humans. Arterioscler Thromb Vasc Biol 2005 ; 25 : 1891-5.

13) Chen CH, et al. Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart. Science 2008 12 ; 321 : 1493-5.

P.228 掲載の参考文献

1) 安部和夫. ニトロプルシドナトリウム. Anesthesia 21 Century 2008 ; 10 : 41-4.

2) Johnson CC. Mechanisms of actions and toxicity of nitroprusside. Proc Soc Exp Biol Med. 1928 ; 26 : 102-3.

3) Page IH, et al. Cardiovascular actions of sodium nitroprusside in animals and hypertensive patients. Circulation 1955 ; 11 : 188-98.

4) Moraca PP, et al. Clinical evaluation of sodium nitroprusside as a hypotensive agent. Anesthesiology. 1962 ; 23 : 193-9.

5) Friederich JA, Butterworth IV JF. Sodium nitroprusside : Twenty years and counting. Anesth Analg 1995 ; 81 : 152-62.

6) 大野博司. ICU/CCUの薬の考え方, 使い方. 東京 : 中外医学社 ; 2011. p. 283-5.

P.230 掲載の参考文献

1) 田村貴彦, ほか. 冠攣縮の急性期薬物治療-冠拡張薬はすみやかに, そして十分に! LiSA 2013 ; 20 : 754-9.

P.232 掲載の参考文献

1) 吉嶺孝和, ほか. Prostaglandin E1の低血圧麻酔への応用. 麻酔 1981 ; 30 : 664-71.

2) Koch JA, et al. Prostaglandin E1 : A new agent for the prevention of renal dysfunction in high risk patients caused by radiocontrast media? PGE1 Study Group. Nephrol Dial Transplant 2000 ; 15 : 43-9.

3) 嶋田紘 (監修). PGE1の肝保護作用-最新の知見. 東京 : 診断と治療社 ; 2004.

P.236 掲載の参考文献

1) Fleisher LA, et al. 2009 ACCF/AHA focused update on perioperative beta blockade incorporated into the ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery : A report of the American college of cardiology foundation/American heart association task force on practice guidelines. Circulation 2009 ; 120 : e169-276.

2) JCS Joint Working Group. Guidelines for perioperative cardiovascular evaluation and management for noncardiac surgery (JCS 2008) --digest version. Circ J 2011 ; 75 : 989-1009.

3) Lauer MS, et al. Atrial fibrillation following coronary artery bypass surgery. Prog Cardiovasc Dis 1989 ; 31 : 367-78.

4) Amar D. Perioperative atrial tachyarrhythmias. Anesthesiology 2002 ; 97 : 1618-23.

5) Polanczyk CA, et al. Supraventricular arrhythmia in patients having noncardiac surgery : Clinical correlates and effect on length of stay. Ann Intern Med 1998 ; 129 : 279-85.

6) McCord J, Borzak S. Multifocal atrial tachycardia. Chest 1998 ; 113 : 203-9.

7) O'Kelly B, et al. Ventricular arrhythmias in patients undergoing noncardiac surgery. The Study of Perioperative Ischemia Research Group. JAMA 1992 ; 268 : 217-21.

P.240 掲載の参考文献

1) 内藤裕史. アトロピン, ベラドンナアルカロイド. 内藤裕史. 中毒百科-事例・病態・治療. 第2版. 東京 : 南江堂 ; 2001. p. 521-3.

2) Brown JH, Taylor P. Muscarinic receptor agonists and antagonists,, In Brunton LL, ed. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 11th ed. New York ; McGraw-Hill ; 2006. p. 183-200.

3) 黒澤美枝子. 自律神経系. 小澤瀞司, 福田康一郎, 総編. 標準生理学. 第7版. 東京 : 医学書院 ; 2009. p. 400-22.

4) Neumar RW, et al. Part 8 : adult advanced cardiovascular life support : 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010 ; 122 (18 Suppl 3) : S729-67.

5) 内藤裕史. 有機リン系殺虫剤. 内藤裕史. 中毒百科-事例・病態・治療. 第2版. 東京 : 南江堂 ; 2001. p. 230-48.

P.243 掲載の参考文献

1) Fleisher LA, et al. 2009 ACCF/AHA focused update on perioperative beta blockade incorporated into the ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery : A report of the American college of cardiology foundation/American heart association task force on practice guidelines. Circulation 2009 ; 120 : e169-276.

2) 小野善平, 谷口興一. 塩酸ランジオロール. 循環制御 2003 ; 24 : 84-6.

3) 新博次, ほか. 超短時間作用型β1遮断薬塩酸ランジオロール (ONO-1101) の各種頻脈性不整脈に対する効果ならびに薬物動態. 臨床医薬 1997 ; 13 : 4851-72.

4) Sakamoto A, et al. Landiolol, an ultra-short-acting beta (1) -blocker, more effectively terminates atrial fibrillation than diltiazem after open heart surgery : Prospective, multicenter, randomized, open-label study (JL-KNIGHT study). Circ J 2012 ; 76 : 1097-101.

5) Sakamoto A, et al. Perioperative landiolol administration reduces atrial fibrillation after cardiac surgery : A meta-analysis of randomized controlled trials. Adv The 2014 ; 31 : 440-50.

6) 森嶌淳友, ほか. 急性大動脈解離術後における塩酸ランジオロールの心房細動抑制効果についての検討. 日血外会誌 2009 ; 18 : 481-5.

7) Shikada Y, et al. The effect of landiolol on prevention for supraventricular arrhythmia after thoracic surgery. 循環制御 2010 ; 31 : 36-8.

8) Nagai R, et al. Urgent management of rapid heart rate in patients with atrial fibrillation/flutter and left ventricular dysfunction : Comparison of the ultra-short-acting beta1-selective blocker landiolol with digoxin (J-Land Study). Circ J 2013 ; 77 : 908-16.

P.246 掲載の参考文献

1) Royster RL, et al. Cardiovascular pharmacology. In : Kaplan JA, et al, eds. Kaplan's Cardiac Anesthesia. 5th ed. Philadelphia : Saunders ; 2006. p. 213-80.

2) Brunton LL. Treatment of myocardial ischemia. In : Brunton LL, ed. Goodman & Gilman's The Pharmachological Basis of Therapeutics. 11th ed. New York : McGraw-Hill ; 2006. p. 832-8.

3) Covino BG. Perioperative management of arrhythmias. In : Kaplan JA. Cardiac Anesthesia, vol 2. Cardiovascular Pharmacology. New York : Grune & Stratton ; 1983. p. 395-412.

4) 中谷晴昭. 不整脈診療の基本「心筋とイオンチャネル」. Intensivist 2009 ; 1 : 681-9.

5) 外須美夫. 循環生理. 花岡一雄, 編. 麻酔生理学. 東京 : 真興交易医書出版部 ; 2001. p. 88-118.

P.250 掲載の参考文献

1) de Oliveira FC, et al. Use of beta-blockers for the treatment of cardiac arrest due to ventricular fibrillation/pulseless ventricular tachycardia : A systematic review. Resuscitation 2012 ; 83 : 674-83.

2) Schroeppel TJ, et al. Traumatic brain injury and β -blockers : Not all drugs are created equal. J Trauma Acute Care Surg 2014 ; 76 : 504-9.

3) Lerman BB, et al. Mechanisms of idiopathic left ventricular tachycardia. J Cardiovasc Electrophysiol 1997 ; 8 : 71-83.

4) Iwai S, Lerman BB. Management of ventricular tachycardia in patients with clinically normal hearts. Curr Cardiol Rep 2000 ; 2 : 515-21.

5) Van Gelder IC, et al ; RACE II Investigators. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 2010 ; 362 : 1363-73.

6) 日本循環器学会, ほか (班長 : 井上博). 心房細動治療 (薬物) ガイドライン (2013年改訂版). p. 1-60. http://www.j-circ.or.jp/guideline/pdf/JCS2013_inoue_h.pdf

P.253 掲載の参考文献

1) Karim A, et al. Clinical pharmacokinetics of disopyramide. J Pharmacokinet Biopharm 1982 ; 10 : 465-94.

2) 藤井諄一, ほか. 健常人におけるDisopyramide Phosphate 50mg静注後の血中濃度ならびにその心機能および諸臨床検査値に対する影響. 薬理と治療 1981 ; 9 (Suppl 1) : 55-63.

3) 抗不整脈薬ガイドライン委員会, 編. 抗不整脈薬ガイドライン-CD-ROM版ガイドラインの解説とシシリアンガンビットの概念. 東京 : ライフメディコム ; 2000.

4) 日本循環器学会, ほか. 不整脈薬物治療に関するガイドライン (2009年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2009_kodama_h.pdf

5) Lafuente-Lafuente C, et al. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev 2012 ; 5 : CD005049.

6) 齋藤寛和, ほか. Disopyramide phosphate静注による発作性心房細動の停止. 循環器科 1994 ; 35 : 406-9.

P.255 掲載の参考文献

1) Sampson KJ, Kass RS. Anti-arrhythmic drugs. In : Brunton LL, ed. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 12th ed. New York : McGraw-Hill ; 2011. p. 815-48.

2) Klabunde RE. Sodium channel blockers. In : Klabunde RE. Cardiovascular Pharmacology Concepts. Philadelphia : Lippincott Williams & Wilkins ; 2011.

3) Sun LS, Schwarzenberger J. Cellular cardiac physiology. In : Miller RD, ed. Miller's Anesthesia. 6th ed. New York : Elsevier, Churchill Livingstone ; 2005. 心臓細胞生理学. 武田純三, 監修. 稲田英一, ほか監訳. ミラー麻酔科学. 原著第6版. メディカル・サイエンス・インターナショナル ; 2007. p.571-6.

4) American Heart Association. ショックと抗不整脈薬. ACLSプロバイダーマニュアルAHAガイドライン 2010準拠. 東京 : シナジー ; 2012. p. 65-6.

P.257 掲載の参考文献

1) 日本循環器学会, ほか. 不整脈薬物治療に関するガイドライン (2009年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2009_kodama_h.pdf

2) Kulick DL, Rahimtoola SH. Current role of digitalis therapy in patients with congestive heart failure. JAMA 1991 ; 265 : 2995-7.

3) Hollevoet I, et al. Medication in the perioperative period : Stop or continue? A review. Acta Anaesth Belg 2011 ; 62 : 193-201.

P.259 掲載の参考文献

1) 加藤林也, ほか. 抗不整脈薬Mexiletine注射剤のPharmacokineticsと期外収縮抑制効果 (第1報). 薬理と治療 1983 ; 11 : 3105-11.

2) Ohashi K, et al. Pharmacokinetics and the Antiarrhythmic effect of mexiletine in patients with chronic ventricular arrhythmias. Arzneimittelforschung 1984 ; 34 (4) : 503-7.

3) 山田和生, ほか. 心室性期外収縮に対するMexiletine注射薬静脈内1回投与の臨床効果-Lidocaine注射薬を対照薬とする多施設共同二重盲検試験. 基礎と臨床 1986 ; 20 (2) : 531-51.

4) Dejgard A, et al. Mexiletine for treatment of chronic painful diabetic neuropathy. Lancet 1988 ; 1 : 9-11.

5) 加藤貴雄. 不整脈薬物療法の新しい考え方Sicilian Gambitの臨床応用. Journal of Nippon Medical School 2002 ; 69 : 7-12.

P.262 掲載の参考文献

1) 医薬品インタビューフォーム「アンカロン(R) 注150 (改訂第5版) 」. 東京 : サノフィ株式会社 (提携 ; 大正富山医薬品株式会社) ; 2013.

2) White CM, et al. Intravenous plus oral amiodarone, atrial septal pacing, or both strategies to prevent post-cardiothoracic surgery atrial fibrillation : The Atrial Fibrillation Suppression Trial II (AFIST II). Circulotion 2003 ; 108 (Suppl 1) : II 200-6.

3) American Heart Association. ACLSプロバイダーマニュアル AHAガイドライン 2010準拠. 東京 : シナジー ; 2012.

P.266 掲載の参考文献

1) 佐野秀年. シンビット静注用50 mg (III群抗不整脈薬). CIRCULATION Up-to-Date 2006 ; 1 : 270-3.

2) 志賀剛. III群抗不整脈薬の使い分け. CIRCULATION Up-to-Date 2011 ; 6 : 406-15.

3) 小谷部明広, 佐野秀年. III群抗不整脈薬塩酸ニフェカラント (シンビット(R) 注) の薬理作用および臨床効果. 日薬理誌 2002 ; 119 : 103-9.

4) 池田隆徳. 循環器薬の使い方とコツb. 不整脈治療 (2) III群抗不整脈薬. Heart View 2010 ; 14 : 167-71.

5) 高野照夫. ICU・CCUにおける治療指針-病態にあった迅速・的確な診療のために (第1回) ニフェカラントの的確な使い方. ICUとCCU 2010 ; 34 : 87-9.

6) Shiga T, et al. Reverse use-dependent QT prolongation during infusion of nifekalant in a case of recurrent ventricular tachycardia with old myocardial infarction. J Electrocardiol 2001 ; 34 : 77-80.

7) 栗田隆志. 不整脈薬物療法における患者フォローと病診連携のポイント-副作用マネジメントから考える抗不整脈薬の選択. Progress in Medicine 2010 ; 30 : 1629-32.

8) Shiga T, et al. Antiarrhythmic effect of nifekalant on atrial tachyarrhythmia in four patients with severe heart failure. J Cardiol 2002 ; 39 : 159-64.

P.272 掲載の参考文献

1) 公益社団法人日本麻酔科学会. 麻酔薬および麻酔関連薬使用ガイドライン第3版 XII その他. 2012 第3版第3訂 2012.10.31 (他-16). http://www.anesth.or.jp/guide/pdf/publication4-12_20121106.pdf

P.275 掲載の参考文献

1) Brater DC. Resistance to diuretics : Emphasis on a pharmacological perspective. Drugs 1981 ; 22 : 477-94

2) Pichette V, et al. Role of plasma protein binding on renal metabolism and dynamics of furosemide in the rabbit. Drug Metab Dispos 1999 ; 27 : 81-5.

3) Di Stefano A, et al. Transepitelial Ca2+ and Mg2+ transport in the cortical thick ascending limb of Henle's loop of the mouse is a voltage-dependent process. Ren Physiol Bilchem 1993 ; 16 : 157-66.

4) Goodman LS, Gilman A. 大森義仁, ほか監訳, グッドマン・ギルマン薬理書-薬物治療の基礎と臨床上. 第6版. 東京 : 廣川書店 ; 1986. p. 938, 954.

5) Sanjay S, et al. The comparison of the diuretic and natriuretic efficacy of continuous and bolus intravenous furosemide in patients with chronic kidney disease. Nephrology (Carlton) 2008 ; 13 : 247-50.

6) Felker GM, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 2011 ; 364 : 797-805.

7) Karajala V, et al. Diuretics in acute kidney injury. Minerva Anesthesiol 2009 ; 75 : 251-7.

8) Ho KM, Power BM. Benefits and risks of furosemide in acute kidney injury. Anaesthesia 2010 ; 65 ; 283-93.

9) Pacifici GM. Clinical pharmacology of furosemide in neonates : A review. Pharmaceuticals (Basei) 2013 ; 6 : 1094-129.

10) Pichette V, et al. The influence of moderate hypoalbuminaemia on the renal metabolism and dynamics of furosemide in the rabbit. Br J Pharmacol 1996 ; 119 : 885-90.

11) Gerber JG, Nies AS. Furosemide induced vasodilation : Importance of state of hydration and filtration. Kidney Int 1980 ; 18 : 454-9.

12) Ho KM, Sheridan DJ. Meta-analysis of furosemide to prevent or treat acute renal failure. BMJ 2006 ; 333 : 420.

P.277 掲載の参考文献

1) 公益社団法人日本麻酔科学会. 麻酔薬および麻酔関連薬使用ガイドライン第3版 XII その他. 2012 第3版第3訂 2012.10.31 (他-16). http://www.anesth.or.jp/guide/pdf/publication4-12_20121106.pdf

P.280 掲載の参考文献

1) 今井正. 利尿薬. 佐々木成, 石橋賢一, 編. からだと水の事典. 東京 : 朝倉書店 ; 2008. p. 322-27.

2) Lapi D, et al. Pial microvascular responses to transient bilateral common carotid artery occlusion : Effects of hypertonic glycerol. J Vasc Res 2008 ; 45 : 89-102.

3) Preston GM, Agre P. Isolation of the cDNA for erythrocyte integral membrane protein of 28 kilodaltons : Member of an ancient channel family. Proc Natl Acad Sci U S A 1991 ; 88 : 11110-4.

4) 日本薬局方解説書編集委員会, 編. 第十五改正日本薬局方解説書. 東京 : 廣川書店 ; 2006.

5) 佐々木成. アクアポリンの病気. 佐々木成, 石橋賢一, 編. からだと水の事典. 東京 : 朝倉書店 ; 2008. p. 64-70.

6) 祖父江和哉. 脳における水チャンネル <アクアポリン>の機能と脳浮腫への関与. Nagoya Med J 2010 ; 50 : 199-205.

7) 田村哲也, 祖父江和哉. 脳浮腫と頭蓋内圧亢進. 救急医学 2013 ; 37 : 1586-90.

8) 福内靖男, ほか. 高張グリセロール静脈内投与による神経疾患の治療 1-10% (W/V) グリセロール加生理食塩液 (CG-A2P) の臨床効果について. 臨牀と研究 1978 ; 55 : 929-37.

9) Yu YL, et al. Treatment of acute cerebral hemorrhage with intravenous glycerol : A double-blind, placebo-controlled, randomized trial. Stroke 1992 ; 23 : 967-71.

10) Manley GT, et al. Aquaporin-4 deletion in mice reduces brain edema after acute water intoxication and ischemic stroke. Nat Med 2000 ; 6 : 159-63.

11) Papadopoulos MC, et al. Aquaporin-4 facilitates reabsorption of excess fluid in vasogenic brain edema. FASEB J 2004 ; 18 : 1291-3.

P.283 掲載の参考文献

1) Malhotra V, Pamnani A. Renal, liver, and biliary tract disease. Miller RD, Pardo, Jr. MC. Basics of Anesthesia. 6th ed. Elsevier ; 2011. p. 448-62.

2) 田中昌代, ほか. 体内薬物動態を基にした頭蓋内圧亢進時のマンニトールの至適投与方法. Neurological Surgery 1991 ; 19 : 619-24.

3) Parry WL, et al. Experimental studies of acute renal failure. I. the protective effect of mannitol. J Urol 1963 ; 89 : 1-6.

4) 卜部美代志ほか. 未発表

5) Barry KG, et al. Mannitol and isosorbide. Sequential effects on intraocular pressure, serum osmolality, sodium, and solids in normal subjects. Arch Ophtalmol 1969 ; 81 : 695-700.

6) Cote CJ, et al. The hypotensive response to rapid intravenous administration of hypertonic solutions in man and in the rabbit. Anesthesiology 1979 ; 50 : 30-5.

7) 田村哲也, 祖父江和哉. 脳浮腫と頭蓋内圧亢進. 救急医学 2013 ; 37 : 1586-90.

8) Bereczki D, et al. Cochrane report : A systemic review of mannitol therapy for acute ischemic stroke and cerebral parenchymal hemorrhage. Stroke 2000 ; 31 : 2719-22.

9) Gunby P. Mannitol opens pathway of brain tumor chemotherapy. JAMA 1981 ; 245 : 1802.

10) Wu CT, et al. A comparison of 3% hypertonic saline and mannitol for brain tumor surgery. Anesth Analg 2010 ; 110 : 903-7.

P.290 掲載の参考文献

1) Liccardi G, et al. The risk of bronchospasm in asthmatics undergoing general anaesthesia and/or intravascular administration of radiographic contrast media. Physiopatology and clinical/functional evaluation. Eur Ann Allergy Clin Immunol 2010 ; 42 : 167-73.

2) Warner DO, et al. Perioperative respiratory complications in patients with asthma. Anesthesiology 1996 ; 85 : 460-7.

3) Liccardi G, et al. Control of asthma for reducing the risk of bronchospasm in asthmatics undergoing general anesthesia and/or intravascular administration of radiographic contrast media. Curr Med Res Opin 2009 ; 25 : 1621-30.

4) Schwilk B, wt al. Perioperative respiratory events in smokers and nonsmokers undergoing general anaesthesia. Acta Anaesthesiol Scand 1997 ; 41 : 348-55.

5) Berend N, et al. Mechanisms of airway hyperresponsiveness in asthma. Respirology 2008 ; 13 : 624-31.

6) Liccardi G, et al. Bronchial asthma. Curr Opin Anaesthesiol 2012 ; 25 : 30-7.

7) D'Alonzo GE. Theophylline revisited. Allergy Asthma Proc 1996 ; 17 : 335-9.

8) 谷口正実. アスピリン喘息における点滴静注ステロイド薬の使い方. アレルギーの臨床 2003 ; 23 : 87-9.

9) Goff MJ, et al. Absence of bronchodilation during desflurane anesthesia : A comparison to sevoflurane and thiopental. Anesthesiology 2000 ; 93 : 404-8.

10) Eames WO, et al. Comparison of the effects of etomidate, propofol, and thiopental on respiratory resistance after tracheal intubation. Anesthesiology 1996 ; 84 : 1307-11.

11) Pizov R, et al. Wheezing during induction of general anesthesia in patients with and without asthma. A randomized, blinded trial. Anesthesiology 1995 ; 82 : 1111-6.

12) Rowe BH, et al. Magnesium sulfate for treating exacerbations of acute asthma in the emergency department. Cochrane Database Systematic Revs 2000 : CD001490.

13) Hashemian SM, Fallahian F. The use of heliox in critical care. Int J Crit Illn Inj sci 2014 ; 4 : 138-42.

P.293 掲載の参考文献

1) Naclerio RM, et al. Theophylline reduces the response to nasal challenge with antigen. Am J Med 1985 ; 79 6A : 43-7.

2) Finnerty JP, et al. Effects of theophylline on inflammatory cells and cytokines in asthmatic subjects : A placebo-controlled parallel group study. Eur Respir J 1996 ; 9 : 1672-7.

3) Sullivan P, et al. Anti-inflammatory effects of low-dose oral theophylline in atopic asthma. Lancet 1994 ; 343 : 1006-8.

4) Minoguchi K, et al. Effect of theophylline withdrawal on airway inflammation in asthma. Clin Exp Allergy 1998 ; 28 (Supple 3) : 57-63.

5) Ohta K, et al. The prolonged survival of human eosinophils with interleukin-5 and its inhibition by theophylline via apoptosis. Clin Exp Allergy 1996 ; 26 (Supple 2) : 10-5.

6) Mary D, et al. Regulation of interleukin 2 synthesis by cAMP in human T cells. J Immunol 1987 ; 139 : 1179-84.

7) Ito K, et al. A molecular mechanism of action of theophylline : Induction of histone deacetylase activity to decrease inflammatory gene expression. Proc Natl Acad Sci U S A 2002 ; 99 : 8921-6.

P.295 掲載の参考文献

1) 渡邉哲也. 皮膚適用製剤の現状と展望-Globalな視点から. Drug delivery system 2007 ; 22 : 450-7.

2) 渡邉哲夫, ほか. ツロブテロール貼付後の血漿中濃度に及ぼす製剤特性と皮膚透過性の影響に関する薬物動態学的解析. YAKUGAKU ZASSHI 2011 ; 131 : 1483-92.

3) 日本医薬品集フォーラム, 監修. ツロブテロール. 日本医薬品集医療薬 2014年版. 東京 : じほう ; 2013. p. 1718-22.

4) Ichinose M, et al. Additive effects of transdermal tulobuterol to inhaled tiotropium in patients with COPD. Respir Med 2010 ; 104 : 267-74.

5) 濱崎雄平, ほか監. 日本小児アレルギー学会. 小児気管支喘息治療・管理ガイドライン 2012. 東京 : 協和企画 ; 2011.

P.299 掲載の参考文献

1) 日本アレルギー学会喘息ガイドライン専門部会, 監修. 「喘息予防・管理ガイドライン 2012」作成委員, 作成. 喘息予防・管理ガイドライン2012. 東京 : 協和企画 ; 2012.

2) 濱崎雄平, ほか監修. 日本小児アレルギー学会, 作成. 小児気管支喘息治療・管理ガイドライン 2012. 東京 : 協和企画 ; 2011.

3) Cheney FW, et al. Adverse respiratory events infrequently leading to malpractice suits. A closed climes analysis. Anesthesiology 1991 ; 75 : 932-9.

P.305 掲載の参考文献

1) 丸栄一, ほか. けいれん重積の定義と病態. 救急・集中治療 2013 ; 25 : 1278-84.

2) Perks A, et al. Anaesthesia and epilepsy. Br J Anaesth 2012 ; 108 : 562-71.

3) 卜部貴夫. けいれん重積の治療. 救急・集中治療 2013 ; 25 : 1293-300.

4) 日本神経学会, 監修. 「てんかん治療ガイドライン」作成委員会, 編. てんかん重積状態. てんかん治療ガイドライン2010. 東京 : 医学書院 ; 2010. p.72-85.

5) 「てんかん治療ガイドライン」作成委員会. てんかん治療ガイドライン 2010 追補版. http://www.neurology-jp.org/guidelinem/tenkan_tuiho.html

6) Neal JM, et al. American Society of Regional Anesthesia and Pain Medicine checklist for managing local anesthetic systemic toxicity : 2012 version. Reg Anesth Pain Med 2012 ; 37 : 16-8.

7) 日本妊娠高血圧学会, 編. 子癇の診断と管理. 妊娠高血圧症候群 (PIH) 管理ガイドライン 2009. http://jsshp.umin.jp/i_7.html. p. 59-72.

8) Euser AG, Cipolla MJ. Magnesium sulfate for the treatment of eclampsia : A brief review. Stroke 2009 ; 40 : 1169-75.

9) Sharma V, et al. The association between tranexamic acid and convulsive seizures after cardiac surgery : A multivariate analysis in 11 529 patients. Anaesthesia 2014 ; 69 : 124-30.

P.308 掲載の参考文献

1) MacDonald RL, Twyman RE. Kinetic properties and regulation of GABA receptor channels. In : Narahashi R, ed. Ion Channels. New York : Plenum Press ; 1992. p. 315-43.

2) Heyer E, Macdonald R. Barbiturate reduction of calcium-dependent action potentials : Correlation with anesthetic action. Brain Res 1982 ; 236 : 157-71.

3) Nelson E, et al. Phenobarbital pharmacokinetics and bioavailability in adults. J Clin Pharmacol 1982 ; 22 : 141-8.

4) Graves NM, et al. Relative bioavailability of rectally administered phenobarbital sodium parenteral solution. DICP 1989 ; 23 : 565-8.

5) Pitlick W, et al. Phenobarbital pharmacokinetics in neonates. Clin Pharmacol Ther 1978 ; 23 : 346-50.

6) Gal P, et al. The influence of asphyxia on phenobarbital dosing requirements in neonates. Dev Pharmacol Ther 1984 ; 7 : 145-52.

7) Heimann G, Gladtke E. Pharmacokinetics of phenobarbital in childhood. Eur J Clin Pharmacol 1977 ; 12 : 305-10.

8) Van Orman C, Darwish HZ. Efficacy of phenobarbital in neonatal seizures. Can J Neurol Sci 1985 ; 12 : 95-9.

9) Shaner MD, et al. Treatment of status epileptics : A prospective comparison of diazepam and phenytoin versus phenobarbital and optional phenytoin. Neorology 1988 ; 38 : 202-7.

10) Crawford TO, et al. Very-high-dose phenobarbital for refractory status epileptics in children. Neurology 1988 ; 38 : 1035-40.

P.311 掲載の参考文献

1) 医薬品インタビューフォーム. 抗けいれん剤「アレビアチン(R) 注250 mg」. 2014年2月改訂 (第16版). 大日本住友製薬株式会社.

2) 医薬品インタビューホーム. 抗けいれん剤「ホストイン(R) 静注750 mg」. 2012年8月作成 (第4版). エーザイ株式会社.

3) 藤村洋太, 千葉茂. てんかんの薬物治療. 吉野相英, 編. 精神科診療エキスパートシリーズ. てんかん診療スキルアップ. 東京 : 医学書院 ; 2014. p. 106 -48.

4) Tunnicliff G. Basis of the antiseizure action of phenytoin. Gen Pharmacol 1996 ; 27 : 1091-7.

5) Wright PM, et al. Influence of chronic phenytoin administration on the pharmacokinetics and pharmacodynamics of vecuronium. Anesthesiology 2004 ; 100 : 626 -33.

6) Spacek A, et al. Augmentation of the rocuronium-induced neuromuscular block by the acutely administered phenytoin. Anesthesiology 1999 ; 90 : 1551 -5.

P.313 掲載の参考文献

1) Fawcett WJ, et al. Magnesium : Physiology and pharmacology. Br J Anaesth 1999 ; 83 : 302-20.

2) Dean C, Douglas MJ. Magnesium and the obstetric anaesthetist. MJ Int J Obstet Anesth 2013 ; 22 : 52-63.

3) Crowther CA, et al. Magnesium sulphate for preventing preterm birth in threatened preterm labour. Cochrane Database Syst Rev 2002 ; 4 : CD001060.

4) Altman D, et al ; Magpie Trial Collaborative Group. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial : A randomised placebo-controlled trial. Lancet 2002 ; 359 : 1877-90.

5) Rouse DJ, et al. A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy. N Engl J Med 2008 ; 359 : 895-905.

6) Gupta K, et al, The role of magnesium as an adjuvant during general anaesthesia. Anaesthesia 2006 ; 61 : 1058-63.

7) De Oliveira GS Jr, et al. Perioperative systemic magnesium to minimize postoperative pain : A meta-analysis of randomized controlled trials. Anesthesiology 2013 ; 119 : 178-90.

P.318 掲載の参考文献

1) Mertes PM, et al. Perioperative anaphylaxis. Immunol Allergy Clin North Am 2009 ; 29 : 429-51.

2) Mertes PM, et al ; Groupe d'Etudes des Reactions Anaphylactoides Peranesthesiques. Anaphylactic and anaphylactoid reactions occurring during anesthesia in France in 1999-2000. Anesthesiology 2003 ; 99 : 536-45.

3) Takazawa T, et al. Three suspected cases of sugammadex-induced anaphylactic shock. BMC Anesthesiol 2014 ; 14 : 92.

4) 高澤知規, ほか. リドカインによるアナフィラキシーショックが疑われた一例. 日臨麻会誌 2013 ; 33 : S355.

5) 堀内辰男, ほか. プロポフォールによる麻酔導入時のアナフィラキシーが疑われた1例. 臨床麻酔 2014 ; 38 : 503-6.

6) Sampson HA, et al. Second symposium on the definition and management of anaphylaxis : Summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 2006 ; 117 : 391-7.

7) Harper NJ, et al. Suspected anaphylactic reactions associated with anaesthesia. Anaesthesia 2009 ; 64 : 199-211.

8) Mertes PM, et al. Reducing the risk of anaphylaxis during anesthesia : 2011 updated guidelines for clinical practice. Investig Allergol Clin Immunol 2011 ; 21 : 442-53.

9) Sheikh A, et al. Adrenaline for the treatment of anaphylaxis : Cochrane systematic review. Allergy 2009 ; 64 : 204-12.

10) Kroigaard et al. Scandinavian Clinical Practice Guidelines on the diagnosis, management and follow-up of anaphylaxis during anaesthesia. Acta anaesthesiol Scand 2007 ; 51 : 655-70.

11) Nurmatov UB, et al. H2-antihistamines for the treatment of anaphylaxis with and without shock : A systematic review. Ann Allergy Asthma Immunol 2014 ; 112 : 126-31.

12) Sheikh A, et al. H1-antihistamines for the treatment of anaphylaxis : Cochrane systematic review. Allergy 2007 ; 62 : 830-7.

13) Clark S, et al. Multicenter study of emergency department visits for food allergies. J Allergy Clin Immunol 2004 ; 113 : 347-52.

14) Rohacek M, et al. Biphasic anaphylactic reactions : Occurrence and mortality. Allergy 2014 ; 69 : 791-7.

15) Choo KJ, et al. Glucocorticoids for the treatment of anaphylaxis : Cochrane systematic review. Allergy 2010 ; 65 : 1205-11.

16) Thomas M, Crawford I. Best evidence topic report. Glucagon infusion in refractory anaphylactic shock in patients on beta-blockers. Emerg Med J 2005 ; 22 : 272-3.

17) 光畑裕正. アナフィラキシーショックの治療指針の標準化. Shock 2012 ; 26 : 77-84.

P.321 掲載の参考文献

1) Sanger GJ, King FD. From metoclopramide to selective gut motility stimulants and 5-HT3 receptor antgonists. Drug Des Deliv 1988 ; 3 : 273-95.

2) Henzi I, et al. Metoclopramide in the prevention of postoperative nausea and vomiting : A quantitive systematic review of randomized, placebo-controlled studies. Br J Anaesth 1999 ; 83 : 761-71.

3) De Oliveira GS Jr, et al. Systemic metoclopramide to prevent postoperative nausea and vomiting : A meta-analysis without Fujii's studies. Br J Anaesth 2012 ; 109 : 688-97.

4) Mishriky BM, Habib AS. Metoclopramide for nausea and vomiting prophylaxis during and after Caesarean delivery : A systematic review and meta-analysis. Br J Anaesth 2012 ; 108 : 374-83.

5) Apfel CC, et al. Evidence-based analysis of risk factors for postoperative nausea and vomiting. Br J Anaesth 2012 ; 109 : 742-53.

P.324 掲載の参考文献

1) Flood P, Coates KM. Droperidol inhibits GABAA and neuronal nicotinic receptor activation. Anesthesiology 2002 ; 96 : 987-93.

2) 岩月賢一, ほか. Neuroleptanalgesiaについて. 麻酔 1967 ; 16 : 933-45.

3) Fischler M, et al. The pharmacokinetics of droperidol in anesthetized patients. Anesthesiology 1986 ; 64 : 486-9.

4) Cressman WA, et al. Absorption, metabolism and excretion of droperidol by human subjects following intramuscular and intravenous administration. Anesthesiology 1973 ; 38 : 363-9.

5) Schaub I, et al. Low-dose droperidol (< 1mg or < 15μgkg-1) for the prevention of postoperative nausea and vomiting in adults : Quantitative systematic review of randomised controlled trials. Eur J Anesthesiol 2012 ; 29 : 286-94.

6) 五十洲剛, ほか. ドロペリドールの硬膜外持続注入の至適量の検討. 麻酔 1995 ; 44 : 1014-7.

7) ドロレプタン添付文書. 2009年6月改訂 (第8版). 第一三共株式会社.

8) Habib AS, Gan TJ. Food and drug administration black box warning on the perioperative use of droperidol : A review of the cases. Anesth Analg 2003 ; 96 : 1377-9.

P.326 掲載の参考文献

1) Tramer MR, et al. Efficacy, dose-response, and safety of ondansetron in prevention of postoperative nausea and vomiting : A quantitative systematic review of randomized placebo-controlled trials. Anesthesiology 1997 ; 87 : 1277-89.

2) Roila F, Del Favero A. Ondansetron clinical pharmacokinetics. Clin Pharmacokinet 1995 ; 29 : 95-109.

3) Gan TJ, et al. Consensus guidelines for the management of postoperative nausea and vomiting. Anesth Analg 2014 ; 118 : 85-113.

P.328 掲載の参考文献

1) 渡邉建彦. ヒスタミン. 田中千賀子, 加藤隆一, 編. NEW薬理学. 改訂第4版. 東京 : 南江堂 ; 2002. p. 134-44.

2) 社団法人日本化学療法学会臨床試験委員会皮内反応検討特別部会. 抗菌薬投与に関連するアナフィラキシー対策のガイドライン (2004年版). http://www.chemotherapy.or.jp/guideline/hinai_anaphylaxis_guideline.pdf

P.331 掲載の参考文献

1) Leurs R, et al. H1-antihistamines : Inverse agonism, anti-inflammatory actions and cardiac effects. Clin Exp Allergy 2002 ; 32 : 489-98.

2) Welch MJ, et al. H1-antihistamines and the central nervous system. Clin Allergy Immunol 2002 ; 17 : 337-88.

3) Simons FER, et al. The pharmacokinetics and antihistaminic of the H1 receptor antagonist hydroxyzine. J Allergy Clin Immunol 1984 ; 73 (1 Pt 1) : 69-75.

4) Simons FER, et al. The pharmacokinetics and pharmacodynamics of hydroxyzine in patients with primary biliary cirrhosis. J Clin Pharmacol 1989 ; 29 : 809-15.

5) Moore MR, McColl KE. Therapy of the acute porphyrias. Clin Biochem 1989 ; 22 : 181-8.

6) Briggs GG. Hydroxyzine. In : Briggs GG, et al. Drugs in Pregnancy and Lactation. 5th ed. Baltimore ; Williams & Willkins : 1988. p. 520-1.

P.334 掲載の参考文献

1) Gray JD, et al. Dynamic plasticity : The role of glucocorticoids, brain-derived neurotrophic factor and other trophic factors. Neuroscience 2013 ; 239 : 214-27.

2) Kvaslerud T, et al. Circadian aspects of post-operative morbidity and mortality. Acta Anaesthesiol Scand 2010 ; 54 : 1157-63.

3) Coursin DB, Wood KE. Corticosteroid supplementation for adrenal insufficiency. JAMA 2002 ; 287 : 236-40.

4) Holte K, Kehlet H. Perioperative single-dose glucocorticoid administration : Pathophysiologic effects and clinical implications. J Am Coll Surg 2002 ; 195 : 694-712.

5) 日本麻酔科学会. 麻酔薬および麻酔関連薬使用ガイドライン第3版. 2012. http://www.anesth.or.jp/guide/pdf/publication4-12_20121106.pdf, p.660-3.

P.337 掲載の参考文献

1) 服部裕一. 糖質コルチコイドの作用と機序. ICUとCCU 2011 ; 35 : 597-604.

2) 日本集中治療医学会Sepsis Registry委員会. 日本版敗血症診療ガイドライン. 日集中医誌 2013 ; 20 : 124-73.

3) Tang BM, et al. Use of corticosteroids in acute lung injury and acute respiratory distress syndrome : A systematic review and meta-analysis. Crit Care Med 2009 ; 37 : 1594-603.

4) Nebelsiek, et al. Routine use of corticosteroids to prevent inflammation response in cardiac surgery. Recent Pat Cardiovasc Drug Discov 2012 ; 7 : 170-4.

5) Bydon M, et al. The Current Role of Steroids in Acute Spinal Cord Injury. World Neurosurg 2014 ; 82 : 848-54.

P.339 掲載の参考文献

1) Apfel CC, et al. A factorial trial of six interventions for the prevention of postoperative nausea and vomiting. N Engl J Med 2004 ; 350 : 2441-51.

2) De Oliveira GS Jr, et al. Dexamethasone to prevent postoperative nausea and vomiting : An updated meta-analysis of randomized controlled trials. Anesth Analg 2013 ; 116 : 58-73.

3) Gan TJ, et al. Consensus guidelines for the management of postoperative nausea and vomiting. Anesth Analg 2014 ; 118 : 85-113.

4) Waldron NH, et al. Impact of perioperative dexamethasone on postoperative analgesia and side-effects : Systematic review and meta-analysis. Br J Anaesth 2013 ; 110 : 191-200.

5) Choi S, et al. Effects of dexamethasone as a local anaesthetic adjuvant for brachial plexus block : A systematic review and meta-analysis of randomized trials. Br J Anaesth 2014 ; 112 : 427-39.

6) Rezonja K, et al. Dexamethasone produces dose-dependent inhibition of sugammadex reversal in in vitro innervated primary human muscle cells. Anesth Analg 2014 ; 118 : 755-63.

P.348 掲載の参考文献

1) 浅田祐士郎. 病的血栓形成のプロセス. LiSA 2010 ; 5 : 428-31.

2) 日本循環器学会, ほか (班長 : 堀正二). 循環器病の診断と治療に関するガイドライン (2008年度合同研究班報告). 循環器疾患における抗凝固・抗血小板療法に関するガイドライン (2009年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2009_hori_h.pdf

3) 尾崎由基男. 種類と作用機序から, モニタリングまで. LiSA 2010 ; 5 : 432-6.

4) Hall R, Mazer CD. Antiplatelet drugs : A review of their pharmacology and management in the perioperative period. Anesth Analg 2011 ; 112 : 292-318.

5) Douketis JD, et al. Perioperative management of antithrombotic therapy : Antithrombotic Therapy and Prevention of Thrombosis, 9th ed : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012 ; 141 : e326S-50S.

6) Kimura T, et al. Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation. Circulation 2009 ; 119 : 987-95.

7) Newsome LT, et al. Coronary artery stents : II. Perioperative considerations and management. Anesth Analg 2008 ; 107 : 570-90.

8) Chassot PG, et al. Perioperative use of anti-platelet drugs. Best Pract Res Clin Anaesthesiol 2007 ; 21 : 241-56.

9) Chassot PG, et al. Perioperative antiplatelet therapy : The case for continuing therapy in patients at risk of myocardial infarction. Br J Anaesth 2007 ; 99 : 316-28.

10) 松原由美子. 抗血小板薬不応性. J Jpn Coll Angiol 2011 ; 51 : 309-14.

11) Seidel H, et al. Monitoring of antiplatelet therapy. Current limitations, challenges, and perspectives. Hamostaseologie 2011 ; 31 : 41-51.

12) Horlocker TT, et al. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy : American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Third Edition). Reg Anesth Pain Med 2010 ; 35 : 64-101.

13) Gogarten W, et al. Regional anaesthesia and antithrombotic agents : Recommendations of the European Society of Anaesthesiology. Eur J Anaesthesiol 2010 ; 27 : 999-1015.

P.351 掲載の参考文献

1) Collaborative overview of randomized trials of antiplatelet therapy--I : Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994 ; 308 : 81-106.

2) Patrono C, et al. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005 ; 353 : 2373-83.

3) Antithrombotic Trialists' Collaboration. Collabo-rative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002 ; 324 : 71-86.

P.353 掲載の参考文献

1) Jacobson AK. Platelet ADP receptor antagonists : ticlodipine and clopidogrel. Best Practice & Research Clinical Haematology 2004, 17 : 55-64.

P.358 掲載の参考文献

1) Furie KL, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack : A guideline for healthcare professionals from the american heart association/american stroke association. Stroke 2011 ; 42 : 227-76.

2) Jneid H, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/Non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update) : A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2012 ; 126 : 875-910.

3) Hall R, Mazer CD. Antiplatelet drugs : A review of their pharmacology and management in the perioperative period. Anesth Analg 2011 ; 112 : 292-318.

4) Angiolillo DJ, et al. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery : A randomized controlled trial. JAMA 2012 ; 307 : 265-74.

5) Holmes MV, et al. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events : A systematic review and meta-analysis. JAMA 2011 ; 306 : 2704-14.

6) Chassot PG, et al. Perioperative antiplatelet therapy. Am Fam Physician 2010 ; 82 : 1484-9.

7) Di Minno MN, et al. Perioperative handling of patients on antiplatelet therapy with need for surgery. Intern Emerg Med 2009 ; 4 : 279-88.

8) Douketis JD, et al. Perioperative management of antithrombotic therapy : Antithrombotic Therapy and Prevention of Thrombosis, 9th ed : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012 ; 141 : e326S-50S.

P.361 掲載の参考文献

1) Shinohara Y, et al. Cilostazol for prevention of secondary stroke (CSPS 2) : An aspirincontrolled, double-blind, randomised non-inferiority trial. Lancet Neurol 2010 ; 9 : 959-68.

2) 呼吸器感染症に関するガイドライン作成委員会, 編. 成人院内肺炎診療ガイドライン. 日本呼吸器学会 2008.

3) Shinohara Y, et al. Antiplatelet cilostazol is effective in the prevention of pneumonia in ischemic stroke patients in the chronic stage. Cerebrovasc Dis 2006 ; 22 : 57-60.

P.364 掲載の参考文献

1) Lette J, et al. Safety of dipyridamole testing in 73,806 patients : The Multicenter Dipyridamole Safety Study. J Nucl Cardiol 1995 ; 2 : 3-17.

P.369 掲載の参考文献

1) 香取信之. 周術期の止血凝固管理におけるPoint of Careモニター. 日臨麻会誌 2013 ; 33 : 263-71.

2) 浦野哲盟.線溶療法の考え方と治療薬剤. 血栓止血誌 2009 ; 20 : 398-400.

3) Bates SM, Ginsberg JS. Clinical practice. Treatment of deep-vein thrombosis. N Engl J Med 2004 ; 351 : 268-77.

4) King CS, et al. Moving toward a more ideal anticoagulant : The oral direct thrombin and factor Xa inhibitors. Chest 2013 ; 143 : 1106-16.

5) Baglin T. The role of the laboratory in treatment with new oral anticoagulants. J Thromb Haemost 2013 ; 11 (Suppl 1) : 122-8.

6) Pernod G, et al. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors : Proposals of the working group on perioperative haemostasis (GIHP) -March 2013. Arch Cardiovasc Dis 2013 ; 106 : 382-93.

P.372 掲載の参考文献

1) 朝倉英策. ヘパリン類, アルガトロバン. 朝倉英策, 編著. 臨床に直結する血栓止血学. 東京 : 中外医学社 ; 2013. p. 330-6.

2) 松岡耕二, 佐々木啓子. ヘパラン硫酸プロテオグリカン-細胞と組織のオーガナイザー. 千葉科学大学紀要 2012 ; 5 : 69-76.

3) 萬知子. 抗凝固・肺塞栓症予防. 麻酔 2014 ; 63 : 278-86.

P.375 掲載の参考文献

1) 保田知生. 予防. 瀬尾憲正, 古家仁, 編. 周術期深部静脈血栓/肺血栓塞栓症. 東京 : 克誠堂出版 ; 2013. p. 78-96.

2) Falck-Ytter Y, et al. Prevention of VTE in orthopedic surgery patients : Antithrombotic Therapy and Prevention of Thrombosis, 9th ed : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141 : e278S-325S.

3) Gould MK, et al. Prevention of VTE in nonorthopedic surgical patients : Antithrombotic Therapy and Prevention of Thrombosis, 9th ed : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012 ; 141 : e227S-77S.

4) Lyman GH, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer : American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013 ; 31 : 2189-204.

5) 黒岩政之. III 予防 A 総論硬膜外麻酔は薬物療法と併用可能か? 森正樹, 土岐祐一郎, 編. エキスパートによる消化器外科静脈血栓塞栓症 (VTE) 診療指針. 東京 : 南江堂 ; 2014. p. 47-50.

6) FDA Drug Safety Communication. Updated recommendations to decrease risk of spinal column bleeding and paralysis in patients on low molecular weight heparins. http://www.fda.gov/downloads/Drugs/DrugSafety/UCM373735.pdf

P.379 掲載の参考文献

1) 鈴木巖, 小関靖. 合成Xa阻害薬フォンダパリヌクスナトリウム (アリクストラ (R) 皮下注5 mg, 7.5 mg) の薬理学的特性と臨床試験成績. 日薬理誌 2012 ; 139 : 117-26.

2) Hata T, et al ; Multi-Center Clinical Study Group of Osaka, Colorectal Cancer Treatment Group (MCSGO). Safety of fondaparinux to prevent venous thromboembolism in Japanese patients undergoing colorectal cancer surgery : A multicenter study. Surg Today 2014 ; 44 : 2116-23.

3) Sasaki S, et al. Prospective study on the efficacies of fondaparinux and enoxaparin in preventing venous thromboembolism after hip fracture surgery. J Orthop Sci 2011 ; 16 : 64-70.

4) Fuji T, et al. Fondaparinux prevents venous thromboembolism after joint replacement surgery in Japanese patients. Int Orthop 2008 ; 32 : 443-51.

5) Horlocker TT, et al. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy : American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Third Edition). Reg Anesth Pain Med 2010 Jan-Feb ; 35 : 64-101.

6) 黒岩政之. 硬膜外麻酔は薬物療法と併用可能か?. 左近賢人, 池田正孝, 編エキスパートによる消化器外科静脈血栓塞栓症診療指針. 東京 : 南江堂 ; 2014. p. 47-50.

7) Kobayashi Y, et al. Spinal Epidural Hematoma during Anticoagulant Therapy for Pulmonary Embolism : Postoperative Complications in a Patient with Lung Cancer. Ann Thorac Cardiovasc Surg 2014 Feb 4. [Epub ahead of print]

P.382 掲載の参考文献

1) Wada H, et al. Expert consensus for the treatment of disseminated intravascular coagulation in Japan. Thromb Res 2010 ; 125 : 6-11.

2) Arepally GM, Ortel TL. Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med 2006 ; 355 : 809-17.

3) Tardy-Poncet B, et al. Danaparoid cross-reactivity with heparin-induced thrombocytopenia antibodies : Report of 12 cases. Intensive Care Med 2009 ; 35 : 1449-53.

4) Kelton JG, et al. Nonheparin anticoagulants for heparin-induced thrombocytopenia. N Engl J Med 2013 ; 368 : 737-44.

5) Weitz JI. Blood coagulation and anticoagulant, fibrinolytic, andantiplatelete drugs. In : Brunton LL, et al, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 12th ed. New York : McGraw-Hill ; 2011. p. 850-6.

P.384 掲載の参考文献

1) 松田保. 抗凝固薬アルガトロバン. CURRENT THERAPY 1990 ; 8 : 161-2.

2) 奥宮明子. ダイレクトトロンビン・インヒビターアルガトロバン. 神大院保健紀要 2009 ; 25 : 29-40.

3) 日本薬局方解説書編集委員会, 編. 第十六改正日本薬局方解説書. 東京 : 廣川書店 ; 2011. C-332-8.

4) Bartholomew JR, et al. Argatroban anticoagulation for heparin-induced thrombocytopenia in elderly patients. Drugs Aging 2007 ; 24 : 489-99.

5) Kondo LM, et al. Argatroban for prevention and treatment of thromboembolism in heparin-induced thrombocytopenia. Ann Pharmacother 2001 ; 35 : 440-51.

6) 斉藤朋之ほか. 抗トロンビン薬 (アルガトロバン) を使用したヘパリン起因性血小板減少症患者の拍動下冠動脈バイパス術の麻酔経験. 麻酔 2009 ; 58 : 1169-71.

P.388 掲載の参考文献

1) Majerus PW, Tollefsen DM. Blood coagulation and anticoagulant, thrombolytic, and antiplatelet drugs. In : Lazo JS, et al, eds. Goodman & Gilman's the Pharmacological Basis of Therapeutics. 11th ed. New York : McGraw-Hill ; 2006. p. 1467-88.

2) 日本医薬品集フォーラム, 監修. ワルファリンカリウム. 日本医薬品集医療薬 2013. 東京 : じほう ; 2013. p. 3297-301.

3) Rieder MJ, et al. Effect of VKORC1 haplotypes on transcriptioinal regulation and warfarin dose. N Engl J Med 2005 ; 352 : 2285-93.

4) D'Andrea G, et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 2005 ; 105 : 645-9.

5) 前田琢磨, 宮田茂樹. 抗凝固療法-薬理と周術期管理. 臨床麻酔 2014 ; 38 (臨増) ; 399-409.

6) Levy JH, et al. Perioperative hemostatic management of patients treated with vitamin K antagonists. Anesthsiology 2008 ; 109 : 918-26.

P.391 掲載の参考文献

1) Butterworth J, et al. The pharmacokinetics and cardiovascular effects of a single intravenous dose of protamine in normal volunteers. Anesth Analg 2002 ; 94 : 514-22.

2) 日本医薬品集フォーラム, 監修. プロタミン硫酸塩. 日本医薬品集医療薬 2013. 東京 : じほう ; 2013. p. 2539-40.

3) Majerus PW, Tollefsen DM. Blood coagulation and anticoagulant, thrombolytic, and antiplatelet drugs. In : Lazo JS, et al, eds. Goodman & Gilman's the Pharmacological Basis of Therapeutics. 11th ed. New York : McGraw-Hill ; 2006. p. 1467-88.

4) Nussmeier NA, et al. Protamine reaction. In : Miller RD, ed. Miller's Anesthesia. 7th ed. Philadelphia : Churchill Livingstone ; 2010. p. 1902-3.

P.393 掲載の参考文献

1) 日本脳卒中学会脳卒中医療向上・社会保険委員会rt-PA (アルテプラーゼ) 静注療法指針改訂部会. rt-PA (アルテプラーゼ) 静注療法適正治療指針第二版. 2012年10月. http://www.jsts.gr.jp/img/rt-PA02.pdf

2) Ny T, et al. The structure of the human tissue-type plasminogen activator gene : Correlation of intron and exon structures to functional and structural domains. Proc Natl Acad Sci U S A 1984 ; 81 : 5355-9.

3) 浦野哲盟. 線溶療法. 朝倉英策, 編著. 臨床に直結する血栓止血学. 東京 : 中外医学社 ; 2013. p. 337-41.

P.396 掲載の参考文献

1) クリアクター(R) 医薬品インタビューフォーム. 2010年8月改訂 (改訂第6版). エーザイ株式会社 ; 2010. p. 1-55.

4章輸液, 輸血

P.402 掲載の参考文献

1) Arieff AI. Hyponatremia, convulsions, respiratory arrest, and permanent brain damage after elective surgery in healthy women. N Engl J Med 1986 ; 314 : 1529-35.

2) Arieff AI, et al. Hyponatraemia and death or permanent brain damage in healthy children. BMJ 1992 ; 304 : 1218-22.

3) Holliday MA, Segar WE. The maintenance need for water in parenteral fluid therapy. Pediatrics 1957 ; 19 : 823-32.

4) Woodcock TE, Woodcock TM. Revised Starling equation and the glycocalyx model of transvascular fluid exchange : An improved paradigm for prescribing intravenous fluid therapy. Br J Anaesth 2012 ; 108 : 384-94.

5) Chappell D, et al. A rational approach to perioperative fluid management. Anesthesiology 2008 ; 109 : 723-40.

6) Brandstrup B, et al. Hemorrhage and operation cause a contraction of the extracellular space needing replacement-evidence and implications? A systematic review. Surgery 2006 ; 139 : 419-32.

P.405 掲載の参考文献

1) Rose BD, Theodore WP. Clinical Physiology of Acid-Base and Electrolyte Disorders. 5th ed. New York : McGraw-Hill ; 2001.

2) Guyton AC, Hall JE. Textbook of Medical Physiology. 9th ed. Philadelphia : Saunders ; 1995.

3) Lobo DN, Awad S. Should chloride-rich crystalloids remain the mainstay of fluid resuscitation to prevent "pre-renal" acute kidney injury? : con. Kidney Int 2014 ; 86 : 1096-105.

4) Mccluskey SA, et al. Hyperchloremia after noncardiac surgery is independently associated with increased morbidity and mortality : A propensity-matched cohort study. Anesth Analg 2013 ; 117 : 412-21.

P.408 掲載の参考文献

1) Doherty M, Buggy DJ. Intraoperative fluids : How much is too much? Br J Anaesth 2012 ; 109 : 69-79.

2) Adrogue HJ, et al. Assessing acid-base disorders. Kidney Int 2009 ; 76 : 1239-47.

3) Yunos NM, et al. Association between a chloride-liberal vs chloride-restrictive intravenous fluid administration strategy and kidney injury in critically ill adults. JAMA 2012 ; 308 : 1566-72.

4) Kaye A, Riopelle J. Intravascular fluid and electrolyte physiology. In : Miller RD, ed. Miller's Anesthesia. 7th ed. Philadelphia : Churchill-Livingstone Elsevier ; 2010. p. 1705-38.

5) Brandstrup B, et al. Hemorrhage and operation cause a contraction of the extracellular space needing replacement--Evidence and implications? A systematic review. Surgery 2006 ; 139 : 419-32.

6) Hajiamae H. Rules of thumb. In : Harn RG, ed. Clinical Fluid Therapy in the Perioperative Setting. Cambridge : Cambridge University Press ; 2011. p. 18-28.

P.411 掲載の参考文献

1) 多保悦夫, ほか. 全身麻酔中の血糖の変化-術前・術中輸液の糖濃度の影響. 臨床麻酔 1993 ; 17 : 1313-6.

2) Merimee TJ, Tyson JE. Stabilization of plasma glucose during fasting ; Normal variations in two separate studies. N Engl J Med 1974 ; 291 : 1275-8.

3) Yamasaki K, et al. Effect of intraoperative acetated Ringer's solution with 1% glucose on glucose and protein metabolism. J Anesth 2010 ; 24 : 426-31.

4) Lattermann R, et al. Perioperative glucose infusion and the catabolic response to surgery : The effect of epidural block. Anesth Analg 2003 ; 96 : 555-62.

5) 多保悦夫. 術中の血糖管理について. 体液・代謝管理 2002 ; 18 : 11-3.

P.413 掲載の参考文献

1) Satoh K, et al. Pharmacological study of BRS, a new bicarbonate Ringer's solution, in haemorrhagic shock dogs. Eur J Anaesthesiol 2005 ; 22 : 703-11.

2) Satoh K, et al. Pharmacological study of BRS, a new bicarbonated Ringer's solution, in partially hepatectomized rabbits. Eur J Anaesthesiol 2005 ; 22 : 624-9.

3) 大井良之, ほか. 酢酸リンゲル液を対照とした重炭酸リンゲル液の多施設共同無作為二重盲検試験-開腹手術予定者を対象として. 新薬と臨牀 2007 ; 56 : 2-10.

4) 中山雅康, ほか. 長時間開腹術時の術中輸液としての重炭酸リンゲル液の有用性. 麻酔 2007 ; 56 : 1334-8.

5) 澤田敦史, ほか. Mg2 +添加輸液剤はレミフェンタニル麻酔後のシバリングを予防できるか? 臨床麻酔 2008 ; 32 : 607-11.

6) 前田祥範, ほか. 重炭酸リンゲル液を自作し術中輸液管理を行ったミトコンドリア脳筋症の1症例. 麻酔 2001 ; 50 : 299-303.

7) 浅野真衣子, ほか. 小児開心術における重炭酸リンゲル液の有用性. 麻酔 2009 ; 58 : 897-902.

8) Shimada Y, et al. Effect of bicarbonate Ringer's solution on the acid-base balance in patients undergoing abdominal aortic aneurysm repair. J Nippon Med Sch 2005 ; 72 : 364-9.

P.416 掲載の参考文献

1) Roche M, et al. The antioxidant properties of serum albumin. FEBS Lett 2008 ; 582 : 1783-7.

2) 篠澤洋太郎. 低アルブミン血症に対するアルブミン製剤投与の是非-アルブミンの生理作用からの考察. INTENSIVIST 2011 ; 3 : 486-500.

3) 石倉宏恭, 川野恭雅. アルブミン製剤投与の考え方. 救急医学 2013 ; 37 : 1703-8.

4) 厚生労働省医薬食品局血液対策課. アルブミン製剤の適正使用.「血液製剤の使用指針」(改訂版). 平成17年9月 (平成24年3月一部改正). http://www.mhlw.go.jp/new-infokobetu/iyaku/kenketsugo/yuketuchiryou07/dl/yuketuchiryou07b.pdf

5) 比留間潔. 血漿分画製剤の適正使用. 外科治療 2011 ; 104 : 256-63.

6) SAFE Study Investigators. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 2004 ; 350 : 2247-56.

7) SAFE Study Investigators. Saline or albumin for fluid resuscitation in patients with traumatic brain injury. N Engl J Med 2007 ; 357 : 874-84.

8) SAFE Study Investigators. Impact of albumin compared to saline on organ function and mortality of patients with severe sepsis. Intensive Care Med 2011 ; 37 : 86-96.

P.419 掲載の参考文献

1) Toyoda D, et al. Pros and cons of tetrastarch solution for critically ill patients. J Intensive Care 2014 ; 2 : 23.

2) 小竹良文. 中分子量低置換度ヒドロキシエチルデンプン製剤の特徴と展望. 麻酔 2014 ; 63 : 218-31.

3) Niemi TT, et al. Colloid solutions : A clinical update. J Anesth 2010 ; 24 : 913-25.

4) 小竹良文. 術後回復力強化プログラムからみた周術期輸液管理-目標指向型輸液管理とは? 医学のあゆみ 2012 ; 240 : 827-31.

5) Myburgh JA, Mythen MG. Resuscitation fluids. N Engl J Med 2013 ; 369 : 1243-51.

6) Van der Linden P, Ickx BE. The effects of colloid solutions on hemostasis. Can J Anaesth 2006 ; 53 : S30-9.

P.426 掲載の参考文献

1) 医療関係者のための改正薬事法・血液法説明資料. http://www.mhlw.go.jp/qa/iyaku/yakujihou/index.html

2) Goodnough LT, et al. Concepts of blood transfusion in adults. Lancet 2013 ; 381 : 1845-54.

3) Shander A, Javidroozi M. Strategies to reduce the use of blood products : A US perspective. Curr Opin Anaesthesiol 2012 ; 25 : 50-8.

4) Theusinger OM, et al. Strategies to reduce the use of blood products : A European perspective. Curr Opin Anaesthesiol. 2012 ; 25 : 59-65.

P.430 掲載の参考文献

1) 紀野修一. 周術期輸血の新しい考え方とその実際 Patient Blood Management-患者中心の輸血医療. Lisa 2012 ; 19 : 1150-5.

2) Surgenor SD, et al. The association of perioperative red blood cell transfusions and decreased long-term survival after cardiac surgery. Anesth Analg 2009 ; 108 : 1741-6.

3) Ferraris VA, et al. Surgical outcomes and transfusion of minimal amounts of blood in the operating room. Arch Surg 2012 ; 147 : 49-55.

4) 厚生労働省医薬食品局血液対策課. 血液製剤の使用にあたって第4版. 東京 : じほう ; 2009. p. 45.

5) American Society of Anesthesiologists Task Force on Perioperative Blood Transfusion and Adjuvant Therapies. Practice guidelines for perioperative blood transfusion and adjuvant therapies : An updated report by the American society of anesthesiologists task force on perioperative blood transfusion and adjuvant therapies. Anesthesiology 2006 ; 105 : 198-208.

6) Lundsgaard-Hansen P. Component therapy of surgical hemorrhage : Red cell concentrates, colloids and crystalloids. Bibl Haematol 1980 ; 46 : 147-69.

7) 厚生労働省医薬食品局血液対策課. 血液製剤の使用にあたって第4版. 東京 : じほう ; 2009. p. 29-30.

8) 宮尾秀樹. 麻酔科からみたPatient Blood Management. 医学のあゆみ 2012 ; 243 : 306-10.

9) Koch CG, et al. Duration of red-cell storage and complication after cardiac surgery. N Engl J Med 2008 ; 358 : 1229-39.

10) 日本輸血・細胞治療学会輸血副作用対応ガイド改訂版作成タスクホース委員会, 編. 輸血副反応ガイド. 東京 : 日本輸血・細胞治療学会 ; 2014.

P.433 掲載の参考文献

1) 厚生労働省医薬食品局血液対策課. 血液製剤の使用にあたって第4版. 東京 : じほう ; 2009. p. 51.

2) Lundsgaard-Hansen P. Component therapy of surgical hemorrhage : Red cell concentrates, colloids and crystalloids. Bibl Haematol 1980 ; 46 : 147-69.

3) Hess JR, et al. Damage control resuscitation : The need for specific blood products to treat the coagulopathy of trauma. Transfusion 2006 ; 46 : 685-6.

4) Gonzalez EA, et al. Fresh frozen plasma should be given earlier to patients requiring massive transfusion. J Trauma 2007 ; 62 : 112-9.

5) CRASH-2 trial collaborators, Shakur H, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2) : A randomized, placebo-controlled trial. Lancet 2010 ; 376 : 23-32.

6) 日本赤十字社血液事業本部医薬情報課. 血液製剤投与早見表 (2010年10月改訂版). 東京 : 日本赤十字社 ; 2010.

7) 日本輸血・細胞治療学会輸血副作用対応ガイド改訂版作成タスクホース委員会, 編. 輸血副反応ガイド. 東京 : 日本輸血・細胞治療学会 ; 2014.

P.435 掲載の参考文献

1) 厚生労働省医薬食品局血液対策課. 血液製剤の使用にあたって第4版. 東京 : じほう ; 2009. p. 47-50.

2) 能見俊浩. 高齢者の開心術. 循環動態と凝固機能のバランスを操る輸血管理. Lisa 2012 ; 19 : 1214-21.

3) 日本輸血・細胞治療学会輸血副作用対応ガイド改訂版作成タスクホース委員会, 編. 輸血副反応ガイド. 東京 : 日本輸血・細胞治療学会 ; 2014.

4) 厚生労働省医薬食品局血液対策課. 「輸血療法の実施に関する指針」 (改訂版) 及び「血液製剤の使用指針」平成17年9月 (平成24年3月一部改正). 日本赤十字社 ; 2012. p. 90.

P.438 掲載の参考文献

1) 富田有毅彦, ほか. 胸部大動脈人工血管置換術症例における体外循環離脱後の凝固障害に対するクリオプレシピテートの有効性の検討.麻酔2011 ; 60: 830-4.

2) Hippala ST, et al. Hemostatic factors and replacement of major blood loss with plasmapoor red cell concentrates. Anesth Analg 1995 ; 81: 360-5.

3) 高松純樹. 術中大量出血時の輸血療法. 高松純樹, 監修. 山本晃士, 編. 図解臨床輸血ガイド. 東京 : 文光堂 ; 2011. p.118-32.

4) Weinkove R, Rangarajan S. Fibrinogen concentrate for acquired hypofibrinogenaemic states. Transfus Med 2008 ; 18: 151-7.

5) American Society of Anesthesiologists Task Force on Perioperative Blood Transfusion and Adjuvant Therapies. Practice guidelines for perioperative blood transfusion and adjuvant therapies : An update report by the American Society for Anesthesiologists Task Force on Perioperative Blood Transfusion and Adjuvant Therapies. Anesthesiology 2006 ; 105 : 198-208.

6) 山本晃士, ほか. 術中大量出血を防ぐための新たな輸血治療-クリオプレシピテートおよびフィブリノゲン濃縮製剤投与効果の検討. 日本輸血細胞治療学会誌 2010 ; 56: 36-42.

5章抗菌薬

P.446 掲載の参考文献

1) Maki DG, et al. Prospective randomized trial of povidone-iodine, alcohol, and chlorhexidine for prevention of infection associated with central venous and arterial catheters. Lancet 1991 ; 338 : 339-43.

2) O'Grady NP, et al ; Healthcare Infection Control Practices Advisory Committee (HICPAC). Guidelines for the prevention of intravascular catheter-related infections. Clin Infect Dis 2011 ; 52 : e162-93.

3) Valles J, et al. Prospective randomized trial of 3 antiseptic solutions for prevention of catheter colonization in an intensive care unit for adult patients. Infect Control Hosp Epidemiol 2008 ; 29 : 847-53.

4) Parienti JJ, du et al ; Members of the NACRE Study Group. Alcoholic povidone-iodine to prevent central venous catheter colonization : A randomized unit-crossover study. Crit Care Med 2004 ; 32 : 708-13.

5) Maiwald M, Chan ES. The forgotten role of alcohol : A systematic review and metaanalysis of the clinical efficacy and perceived role of chlorhexidine in skin antisepsis. PLoS One 2012 ; 7 : e44277.

6) Birnbach DJ, et al. Comparison of povidone iodine and DuraPrep, an iodophor-inisopropyl alcohol solution, for skin disinfection prior to epidural catheter insertion in parturients. Anesthesiology 2003 ; 98 : 164-9.

7) Rees A, et al. Chemical burn from povidone-iodine : Case and review. J Drugs Dermatol 2011 ; 10 : 414-7.

8) Darouiche RO, et al. Chlorhexidine-Alcohol versus Povidone-Iodine for Surgical-Site Antisepsis. N Engl J Med 2010 ; 362 : 18-26.

9) Noorani A, et al. Systematic review and meta-analysis of preoperative antisepsis with chlorhexidine versus povidone-iodine in clean-contaminated surgery. Br J Surg 2010 ; 97 : 1614-20.

10) Alexander JW, et al. Updated recommendations for control of surgical site infections. Ann Surg 2011 ; 253 : 1082-92.

11) Antonelli W, et al. Comparison of two systemic antibiotics for the prevention of complications in elective colorectal surgery. Ital J Surg Sci 1985 ; 15 : 255-8.

12) Solomkin JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children : Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 2010 ; 50 : 133-64.

13) Maki DG, et al. Comparative study of cefazolin, cefamandole, and vancomycin for surgical prophylaxis in cardiac and vascular operations. A double-blind randomized trial. J Thorac Cardiovasc Surg 1992 ; 104 : 1423-34.

14) Finkelstein R, et al. Vancomycin versus cefazolin prophylaxis for cardiac surgery in the setting of a high prevalence of methicillin-resistant staphylococcal infections. J Thorac Cardiovasc Surg 2002 ; 123 : 326-32.

15) Engelman R, et al ; Workforce on Evidence-Based Medicine, Society of Thoracic Surgeons. The Society of Thoracic Surgeons practice guideline series : Antibiotic prophylaxis in cardiac surgery, part II : Antibiotic choice. Ann Thorac Surg 2007 ; 83 : 1569-76.

16) Bull AL, et al. Impact of vancomycin surgical prophylaxis on the development of methicillin-sensitive Staphylococcus aureus surgical site infections : Report from Australian Surveillance Data (VICNISS). Ann Surg 2012 ; 256 : 1089-92.

17) Schweizer M, et al. Effectiveness of a bundled intervention of decolonization and prophylaxis to decrease Gram positive surgical site infections after cardiac or orthopedic surgery : Systematic review and meta-analysis. BMJ 2013 ; 346 : f2743.

18) Shime N, et al. Glycopeptide pharmacokinetics in current paediatric cardiac surgery practice. Eur J Cardiothorac Surg 2007 ; 32 : 577-81.

19) Classen DC, et al. The timing of prophylactic administration of antibiotics and the risk surgical-wound infection. N Engl J Med 1992 ; 326 : 281-6.

20) Junker T, et al. Prevention and control of surgical site infections : Review of the Basel Cohort Study. Swiss Med Wkly 2012 ; 142 : w13616.

21) Steinberg JP, et al ; Trial to Reduce Antimicrobial Prophylaxis Errors (TRAPE) Study Group. Timing of antimicrobial prophylaxis and the risk of surgical site infections : Results from the Trial to Reduce Antimicrobial Prophylaxis Errors. Ann Surg 2009 ; 250 : 10-6.

22) Garey KW, et al. Timing of vancomycin prophylaxis for cardiac surgery patients and the risk of surgical site infections. J Antimicrob Chemother 2006 ; 58 : 645-50.

23) 注射用バンコマイシン塩酸塩, 医薬品インタビューフォーム. 2007年6月作成.

24) Hawn MT, et al. Timing of surgical antibiotic prophylaxis and the risk of surgical site infection. JAMA Surg 2013 ; 148 : 649-57.

25) Nelson RL, et al. Antimicrobial prophylaxis for colorectal surgery. Cochrane Database Syst Rev 2009 ; (1) : CD001181.

26) Zanetti G, et al. Intraoperative redosing of cefazolin and risk for surgical site infection in cardiac surgery. Emerg Infect Dis 2001 ; 7 : 828-31.

27) Hirokawa F, et al. Evaluation of postoperative antibiotic prophylaxis after liver resection : A randomized controlled trial. Am J Surg 2013 ; 206 : 8-15.

28) Haga N, et al. A prospective randomized study to assess the optimal duration of intravenous antimicrobial prophylaxis in elective gastric cancer sugery. Int Surg 2012 ; 97 : 169-76.

29) 毛利靖彦. 日本外科感染症学会による術後感染予防薬の投与期間に関するRCT. ラジオNIKKEI感染症TODAY. 提供 : 塩野義製薬株式会社. http://medical.radionikkei.jp/kansenshotoday_pdf/kansenshotoday-140521.pdf (2014.6.30 アクセス)

30) Tamayo E, et al. Comparative study of single-dose and 24-hour multiple-dose antibiotic prophylaxis for cardiac surgery. J Thorac Cardiovasc Surg 2008 ; 136 : 1522-7.

31) Harbarth S, et al. Prolonged antibiotic prophylaxis after cardiovascular surgery and its effect on surgical site infections and antimicrobial resistance. Circulation 2000 ; 101 : 2916-21.

32) Fonseca SN, et al. Implementing 1-dose antibiotic prophylaxis for prevention of surgical site infection. Arch Surg 2006 ; 141 : 1109-13.

33) American Thoracic Society ; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcareassociated pneumonia. Am J Respir Crit Care Med 2005 ; 171 : 388-416.

P.449 掲載の参考文献

1) 野口行雄, ほかAmpicillinによる細菌性心内膜炎治療の解析. 臨牀と研究 1979 ; 56 : 2309-16.

2) 佐藤肇ほか小児科領域におけるAmpicillin (Viccillin 'Meiji') 静注療法に関する検討. Jpn J Antibiot 1972 ; 25 : 91-4.

3) 宮武邦夫. ほか循環器病の診断と治療に関するガイドライン (2007年度合同研究班報告). 感染性心内膜炎の予防と治療に関するガイドライン (2008年改訂版) http://www.j-circ.or.jp/guideline/pdf/JCS2008_miyatake_h.pdf

4) 青木員レジデントのための感染症診療マニュアル. 第2版. 東京 : 医学書院 ; 2008. p. 1-1464.

P.451 掲載の参考文献

1) 柴孝也, ほか. Sulbactam・Ampicillin に関する臨床的検討. Chemotherapy 1988 ; 36 (Suppl 8) : 149-59.

2) 斎藤篤, ほか. Sulbactamの臨床第一相試験. Chemotherapy 1984 ; 32 (Suppl 4) : 192-201.

3) 中西昌美, ほか. Sulbactam/Cefoperazone合剤の人組織内濃度について. Chemotherapy 1984 ; 32 (Suppl 4) : 379-91.

4) Menzel J, et al. Perioperative use of ampicillin/sulbactam, cefoxitin and piperacillin/metronidazole in elective colon and rectum surgery : A prospective and randomized quality control study in 422 patients. Int J Antimicrob Agents 1996 ; 6 Suppl : S79-82.

5) Bouchillon SK, et al. Antimicrobial susceptibility of inpatient urinary tract isolates of gram-negative bacilli in the United States : Results from the study for monitoring antimicrobial resistance trends (SMART) program : 2009-2011. Clin Ther 2013 ; 35 : 872-7.

6) Dervisoglou A, et al. The value of chemoprophylaxis against Enterococcus species in elective cholecystectomy : A randomized study of cefuroxime vs ampicillin-sulbactam. Arch Surg 2006 ; 141 : 1162-7.

7) 今井圓裕, ほか. 日本腎臓学会, 編. CKD診療ガイド 2012. 日腎会誌 2012 ; 54 : 1031-189.

P.455 掲載の参考文献

1) 田中晴雄, 猪越淳嗣. β-ラクタム系抗生物質. 上野芳夫, ほか編. 微生物薬品化学. 改訂第4版. 東京 : 南江堂 ; 2003. p. 197-210.

2) ペントシリン(R) 医薬品インタビューフォーム. 2013年4月 (改訂第12版). 製造販売 : 富山化学工業/ 発売 : 大正富山医薬品.

3) 柴孝也. 高齢者におけるpiperacillinの体内動態の検討. 日化療会誌 2003 ; 51 : 76-86.

4) 三鴨廣繁, 山岸由佳. PK-PD理論に基づいた抗菌薬使用法. ICUとCCU 2008 ; 32 : 269-79.

5) 品川長夫. 周術期抗菌薬投与の基本的な考え方. 日化療会誌 2002 ; 50 : 313-18.

6) Scaglione F. Can PK/PD be used in everyday clinical practice. Int J Antimicrob Agents 2002 ; 19 : 349-53.

P.459 掲載の参考文献

1) 宇治達哉, 橋本好和. β-ラクタマーゼ阻害薬配合抗生物質製剤「注射用タゾバクタムナトリウム・ピペラシリンナトリウム」 (ゾシン(R) 静注用2.25, ゾシン(R) 静注用4.5) の薬理学的特性および臨床効果. 日薬理誌 2009 ; 133 : 351-8.

2) ゾシン(R) 医薬品インタビューフォーム. 2014年11月 (改訂第12版). 製造販売 : 大鵬薬品/発売 : 大正富山医薬品.

3) 柴孝也. Tazobactam/piperacillin (配合比 1 : 8 製剤) の第I相試験. 日化療会誌 2010 ; 58 (Suppl 1) : 1-10.

4) 橋本章司. tazobactam/piperacilln. 臨床と微生物 2009 ; 36 : 299-304.

5) AL-Nawas B, et al. Concentrations of piperacillin-tazobactam in human jaw and hip bone. Ｊ Craniomaxillofac Surg 2008 ; 36 : 468-72.

6) Takesue Y, et al. Nationwide surveillance of antimicrobial susceptibility patterns of pathogens isolated from surgical site infections (SSI) in Japan. J Infect Chemother 2012 ; 18 : 816-26.

P.462 掲載の参考文献

1) Bratzler DW, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm 2013 ; 70 : 195-283.

2) Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 1995 ; 22 : 89-96.

3) Andes DR, Craig. Cephalosporins. In : Mandell GL, et al. eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 7th ed. New York : Elsevier Churchill Livingstone ; 2009 : p. 323-39.

4) 青木洋介. セフェム系抗菌薬の使い方. 抗菌薬適正使用生涯教育テキスト (改訂版). 日本化学療法学会. 2013. p. 63-84.

5) Stryjewski ME, et al. Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin Infect Dis 2007 ; 44 : 190-6.

P.466 掲載の参考文献

1) 日本集中治療医学会Sepsis Registry委員会. 日本版敗血症診療ガイドライン. 日集中医誌 2013 ; 20 : 124-73.

2) 細菌性髄膜炎の診療ガイドライン作成委員会. 細菌性髄膜炎の診療ガイドライン. 神経治療 2007 ; 24 : 69-132.

3) 河野茂. NHCAP (医療・介護関連肺炎) ガイドラインと抗菌薬使用の考え方. 日老医誌 2012 ; 49 : 673-9.

4) 尾内一信. 小児呼吸器感染症ガイドライン-小児. 小児感染免疫 2012 ; 24 : 297-302.

P.469 掲載の参考文献

1) JAID/JSC 感染症治療ガイド委員会, 編. 日本感染症学会, 日本化学療法学会. JAID/JSC感染症治療ガイド 2011. 東京 : ライフサイエンス出版 ; 2012.

2) Ambrose GP, et al. Pharmacodynamic considerations in the treatment of moderate to severe pseudomonal infections with cefepime. J Antimicrob Chemother 2002 ; 49 : 445-53.

3) 日本臨床腫瘍学会, 編. 発熱性好中球減少症 (FN) 診療ガイドライン. 東京 : 南江堂 ; 2012.

4) 代田悠一郎, ほか. セフェピム塩酸塩投与により周期性あるいは律動性脳波所見を呈した2症例. 臨床神経学 2012 ; 52 : 356-9.

P.471 掲載の参考文献

1) Petri WA Jr. Penicillins, cephalosporins, and other β-lactam antibiotics. Brunton LL, ed. Gooman and Gilman's The Pharmacological Basis of Therapeutics. 12th ed. New York : McGraw-Hill ; 2011. p. 1477-503.

2) Nicolau DP. Pharmacokinetic and pharmacodynamic properties of meropenem. Clin Infect Dis 2008 ; 47 : S32-40.

3) 羽田野義郎, 大曲貴夫. カルバペネムと抗MRSA 薬を正しく使用せよ. Intensivist 2011 ; 3 : 91-100.

4) 荒川宜親. 急激に多様化する新型β-ラクタマーゼへの対策強化の緊急性. 化学療法の領域 2012 ; 28 : 26-31.

P.473 掲載の参考文献

1) Morata L, et al. Influence of Multidrug resistance and appropriate empirical therapy on the 30-day mortality rate of pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 2012 ; 56 : 4833-7.

2) Leibovici L, et al. Aminoglycoside drugs in clinical practice : An evidence-based approach. J Antimicrob Chemother 2009 ; 63 : 246-51.

3) Zierhut G, et al. Comparative analysis of the effects of aminoglycosides on bacterial protein synthesis in vitro. Euro J Biochem 1979 ; 98 : 577-83.

4) Mahmoudi L, et al. Influence of sepsis on higher daily dose of amikacin pharmacokinetics in critically ill patients. Eur Rev Med Pharmacol Sci 2013 ; 17 : 285-91.

5) Buijk SE, et al. Experience with a once-daily dosing program of aminoglycosides in critically ill patients. Intensive Care Med 2002 ; 28 : 936-42.

6) Craig WA. Optimizing aminoglycoside use. Crit Care Clin 2011 ; 27 : 107-21.

7) Blaser J. Efficacy of once-and thrice-daily dosing of aminoglycosides in in-vitro models of infection. J Antimicrob Chemother 1991 ; 27 (Suppl C) : 21-8.

8) Craig WA, Vogelman B. The postantibiotic effect. Ann Intern Med 1987 ; 106 : 900-2.

9) Yasmin F, et al. In vitro synergistic effect of ciprofloxacin with aminoglycosides against multidrug resistant-Pseudomonas aeruginosa. Pak J Pharm Sci 2013 ; 26 : 1041-4.

10) Walker RJ, Duggin GG. Drug nephrotoxicity. Annu Rev Pharmacol Toxicol 1988 ; 28 : 331-45.

11) el-Gammal AA, et al. Pharmacokinetics and intramuscular bioavailability of amikacin in chickens following single and multiple dosing. J Vet Pharmacol Ther 1992 ; 15 : 133-42.

12) van Lent-Evers NA, et al. Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome : a cost-effectiveness analysis. Ther Drug Monit 1999 ; 21 : 63-73.

13) Trotman RL, et al. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis 2005 ; 41 : 1159-66.

14) 日本化学療法学会抗菌薬TDMガイドライン作成委員会, 編. 抗菌薬TDMガイドライン. 2011.

P.476 掲載の参考文献

1) Allison MC, et al ; Endoscopy Committee of the British Society of Gastroenterology. Antibiotic prophylaxis in gastrointestinal endoscopy. Gut 2009 ; 58 : 869-80.

2) Committee on Infectious Diseases. The use of systemic fluoroquinolones. Pediatrics 2006 ; 118 : 1287-92.

3) Woodnutt G. Pharmacodynamics to combat resistance. J Antimicrob Chemother 2000 ; 46 (Suppl T1) : 25-31.

4) Hooper DC, Wolfson JS. The fluoroquinolones : Pharmacology, clinical uses, and toxicities in humans. Antimicrob Agents Chemother 1985 ; 28 : 716-21.

5) Pranger AD, et al. Fluoroquinolones, the cornerstone of treatment of drug-resistant tuberculosis : A pharmacokinetic and pharmacodynamic approach. Curr Pharm Des 2011 ; 17 : 2900-30.

6) Turnidge J. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Drugs 1999 ; 58 (Suppl 2) : 29-36.

7) Bertino J Jr, Fish D. The safety profile of the fluoroquinolones. Clin Ther 2000 ; 22 : 798-817;

8) Eisele S, et al. Ciprofloxacin-related acute severe myalgia necessitating emergency care treatment : A case report and review of the literature. Int J Clin Pharmacol Ther 2009 ; 47 : 165-8.

9) Tome AM, Filipe A. Quinolones : Review of psychiatric and neurological adverse reactions. Drug Saf 2011 ; 34 : 465-88.

10) Dichiara AJ, et al. Ciprofloxacin-induced acute cholestatic liver injury and associated renal failure. Case report and review. Minerva Gastroenterol Dietol 2008 ; 54 : 307-15.

11) Khaliq Y, Zhanel GG. Fluoroquinolone-associated tendinopathy : A critical review of the literature. Clin Infect Dis 2003 ; 36 : 1404-10.

12) Stahlmann R, Lode H. Fluoroquinolones in the elderly : Safety considerations. Drugs Aging 2003 ; 20 : 289-302.

13) Briasoulis A, et al. QT prolongation and torsade de pointes induced by fluoroquinolones : Infrequent side effects from commonly used medications. Cardiology 2011 ; 120 : 103-10.

P.479 掲載の参考文献

1) MRSA感染症の治療ガイドライン作成委員会, 編. MRSA感染症の治療ガイドライン. 2013. http://www.kansensho.or.jp/news/gakkai/pdf/guideline_mrsa.pdf

2) Mangram AJ, et al ; The Hospital Infection Control Practices Advisory Committee. Guideline for Prevention of Surgical Site Infection, 1999. Am J Infection Control 1999 ; 27 : 97-134.

3) Bratzler DW, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health-Syst Pharm 2013 ; 70 : 195-283.

4) Cattoir V, Leclercq R. Twenty-five years of shared life with vancomycin-resistant enterococci : Is it time to divorce? J Antimicrob Chemother 2013 ; 68 : 731-42.

5) Centers for Disease Control and Prevention (CDC). Staphylococcus aureus resistant to vancomycin--United States, 2002. MMWR Morb Mortal Wkly Rep 2002 : 51 : 565-7.

6) Askari E, et al. VanA-positive vancomycin-resistant Staphylococcus aureus : Systematic search and review of reported cases. Infect Dis Clin Pract 2013 ; 21 : 91-3.

6章抗ウイルス薬, 抗真菌薬

P.488 掲載の参考文献

1) 日本感染症学会・新型インフルエンザ対策委員会. 日本感染症学会提言-抗インフルエンザ薬の使用適応について (改訂版). 2011. 2. 28. http://www.kansensho.or.jp/influenza/pdf/110301soiv_teigen.pdf

2) American. Academy of Pediatrics. Red Book (R) : 2009 Report of the Committee on Infectious Diseases, 28th ed. 2009. p. 562 -9.

3) 日本小児科学会パリビズマブの使用に関するガイドライン作成検討委員会. RS ウイルス感染症の予防について (日本におけるパリビズマブの使用に関するガイドライン). 日本小児科学会雑誌 2002. 106 : 1288-92.

4) Hunt R. Herpes viruses. Virology Ch11. Microbiology and Immunology On-line. University of South Carolina School of Medicine. http://pathmicro.med.sc.edu/virol/herpes.htm.

5) 深在性真菌症のガイドライン作成委員会, 編. 深在性真菌症の診断と治療のフローチャート. 深在性真菌症の診断・治療ガイドライン 2007. 東京 : 協和企画 ; 2007. p. 1-33.

6) 深在性真菌症のガイドライン作成委員会, 編. 深在性真菌症の診断と治療のフローチャート. 「深在性真菌症の診断・治療ガイドライン 2014」ドラフト版. 2014. p. 1-25. http://www.mycoses.jp/guideline/gl2014.html

7) Miller RF. Pneumocystis carinii infection in non-AID patients. Curr Opin Infect Dis 1999 ; 12 : 371-7.

7章周術期, ICU における栄養

P.494 掲載の参考文献

1) 井上善文, ほか. 周術期. 日本静脈経腸栄養学会, 編. 静脈経腸栄養ガイドライン. 第3版. 東京 : 照林社 ; 2013. p. 222-34.

2) Weimann A, et al. ESPEN Guidelines on Enteral Nutrition : Surgery including organ transplantation. Clin Nutr 2006 ; 25 : 224-44.

3) Fearon KC, et al. Enhanced recovery after surgery : A consensus review of clinical care for patients undergoing colonic resection. Clin Nutr 2005 ; 24 : 466-77.

4) Gustafsson UO, et al. Guidelines for perioperative care in elective colonic surgery : Enhanced Recovery After Surgery (ERASR) Society recommendations. Clin Nutr 2012 ; 31 : 783-800.

5) 岩坂日出男. ERASプロトコールとは-祝! 周術期医療質向上プロトコール完成に向けて. LiSA 2010 ; 17 : 944-9.

6) The Veterans Affairs Total Parenteral Nutrition Cooperative Study Group. Perioperative total parenteral nutrition in surgical patients. N Engl J Med 1991 ; 22 : 525-32.

7) Bozzetti F, et al. Perioperative total parenteral nutrition in malnourished, gastrointestinal cancer patients : A randomized, clinical trial. JPEN J Parenter Enteral Nutr 2000 ; 24 : 7-14.

8) 矢田部智昭, 横山正尚. 飲んで治す! アルジネード(R) ウォーターが変えるインスリン抵抗性. 日臨麻会誌 2013 ; 33 : 796-801.

9) Yamasaki K, et al. Effect of intraoperative acetated Ringer's solution with 1% glucose on glucose and protein metabolism. J Anesth 2010 ; 24 : 426-31.

10) Donatelli F, et al. Intraoperative infusion of amino acids induces anabolism independent of the type of anesthesia. Anesth Analg 2006 ; 103 : 1549-56.

11) Heyland DK, et al. Should immunonutrition become routine in critically ill patients? A systematic review of the evidence. JAMA 2001 ; 286 : 944-53.

12) Kreymann KG, et al. ESPEN Guidelines on Enteral Nutrition : Intensive care. Clin Nutr 2006 ; 25 : 210-23.

13) Singer P, et al. ESPEN Guidelines on Parenteral Nutrition : Intensive care. Clin Nutr 2009 ; 28 : 387-400.

14) Martindale RG, et al. Guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patient : Society of Critical Care Medicine and American Society for Parenteral and Enteral Nutrition : Executive Summary. Crit Care Med 2009 ; 37 : 1757-61.

15) 氏家良人, ほか, 日本呼吸療法医学会栄養管理ガイドライン作成委員会. 急性呼吸不全による人工呼吸患者の栄養管理ガイドライン. 人工呼吸 2010 ; 27 : 75-118.

P.497 掲載の参考文献

1) 氏家良人, ほか. 急性呼吸不全による人工呼吸患者の栄養管理ガイドライン呼吸療法. 人工呼吸 2010 ; 27 : 75-118.

2) Singer P, et al. ESPEN Guidelines on Parenteral Nutrition : Intensive care. Clin Nutr 2009 ; 28 : 387-400.

3) Martindale RG, et al. Guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patient : Society of Critical Care Medicine and American Society for Parenteral and Enteral Nutrition : Executive Summary. Crit Care Med 2009 ; 37 : 1757-61.

4) 井上善文, ほか. 重症病態-外傷, 熱傷, 重症感染症, 多臓器不全. 日本静脈経腸栄養学会, 編. 静脈経腸栄養ガイドライン. 第3版. 東京 : 照林社 ; 2013. p. 235-47.

5) National Institute for Health and Clinical Excellence. Nutrition support in adults : Oral nutrition support, enteral tube feeding and parenteral nutrition. NICE Clinical Guideline CG32. 2006. http://www.nice.org.uk/guidance/cg32

6) 宇佐美眞, ほか. 脂肪乳剤投与-適応と限界は? 静脈経腸栄養 2010 ; 25 : 591-6.

7) 井上善文, ほか. 静脈栄養製剤の種類と選択. 日本静脈経腸栄養学会, 編. 静脈経腸栄養ガイドライン. 第3版. 東京 : 照林社 ; 2013. p. 33-46.

8) 倉本敬二. 静脈栄養剤の種類と特徴. 東海林徹, 編. 図表でわかる栄養療法-基礎から学ぶ臨床. 東京 : じほう ; 2012. p. 122-5.

P.503 掲載の参考文献

1) 日本静脈経腸栄養学会, 編. 静脈経腸栄養ガイドライン. 第3版. 東京 : 照林社 ; 2013.

2) McClave SA, et al. Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient : Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). JPEN J Parenter Enteral Nutr 2009 ; 33 : 277-316.

3) NICE-SUGAR Sturdy Investigators, Finfer S, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009 ; 360 : 1283-97.

4) Okabayashi T, et al. Continuous postoperative blood glucose monitoring and control by artificial pancreas in patients having pancreatic resection : A prospective randomized clinical trial. Arch Surg 2009 ; 144 : 933-7.

P.505 掲載の参考文献

1) McClave SA, et al. Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient : Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). JPEN J Parenter Enteral Nutr 2009 ; 33 : 277-316.

2) 杉浦伸一. 中心静脈栄養法施行時のアミノ酸製剤の選択. 栄養-評価と治療 2009 ; 26 : 328-30.

3) 日本静脈経腸栄養学会, 編. 静脈経腸栄養ガイドライン. 第3版. 東京 : 照林社 ; 2013.

4) Fischer JE,et al. The effect of normalization of plasma amino acids on hepatic encephalopathy in man. Surgery 1976 ; 80 : 77-91.

P.510 掲載の参考文献

1) 日本静脈経腸栄養学会, 編. 静脈経腸栄養ガイドライン. 第3版. 東京 : 照林社 ; 2013.

2) McClave SA,et al.Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient:Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). JPEN J Parenter Enteral Nutr 2009 ; 33 : 277-316.

3) 深柄和彦. 脂肪乳剤の問題点. 静脈経腸栄養 2013 ; 28 : 909-13.

P.514 掲載の参考文献

1) ASPEN Board of Directors. Guidelines for the use of parenteral and enteral nutrition in adult and pediatric patients. JPEN J Parenter Enteral Nutr 2002 ; 26 (1 supl) : 1SA-138SA.

2) Stechmiller JK, et al. Arginine immunonutrition in critically ill patients : A clinical dilemma. Am J Crit Care 2004 ; 13 : 17-23.

3) Weimann A, et al. ESPEN Guidelines on Enteral Nutrition : Surgery including organ transplantation. Clin Nutr 2006 ; 25 : 224-44.

4) Detsky AS, et al. What is subjective global assessment of nutritional status? JPEN J Parenter Enteral Nutr 1987 ; 11 : 8-13.

5) Kreymann KG, et al. ESPEN Guidelines on Enteral Nutrition : Intensive care. Clin Nutr 2006 ; 25 : 210-23.

6) 日本静脈経腸栄養学会, 編. 静脈経腸栄養ガイドライン第2版-静脈・経腸栄養を適正に実施するためのガイドライン. 東京 : 南江堂 ; 2006.

7) Singer P, et al. ESPEN Guidelines on Parenteral Nutrition : Intensive care. Clin Nutr 2009 ; 28 : 387-400.

8) Braga M, et al. ESPEN Guidelines on Parenteral Nutrition : Surgery. Clin Nutr 2009 ; 28 : 378-86.

9) McClave SA, et al ; A.S.P.E.N. Board of Directors and the American College of Critical Care Medicine. Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient : Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). JPEN J Parenter Enteral Nutr 2009 ; 33 : 277-316.

10) 日本静脈経腸栄養学会, 編. 静脈経腸栄養ガイドライン第3版-静脈・経腸栄養を適正に実施するためのガイドライン. 東京 : 照林社 ; 2013.

11) Lewis SJ, et al. Early enteral nutrition within 24 h of intestinal surgery versus later commencement of feeding : A systematic review and meta-analysis. J Gastrointest Surg 2009 ; 13 : 569-75.

書評

書評を投稿する

最近チェックした商品履歴

Loading...